����JFIFXX�����    $.' ",#(7),01444'9=82<.342  2!!22222222222222222222222222222222222222222222222222����"��4�� ���,�PG"Z_�4�˷����kjز�Z�,F+��_z�,�© �����zh6�٨�ic�fu���#ډb���_�N�?��wQ���5-�~�I���8����TK<5o�Iv-�����k�_U_�����~b�M��d����Ӝ�U�Hh��?]��E�w��Q���k�{��_}qFW7HTՑ��Y��F�?_�'ϔ��_�Ջt��=||I ��6�έ"�����D���/[�k�9���Y�8ds|\���Ҿp6�Ҵ���]��.����6�z<�v��@]�i%��$j��~�g��J>��no����pM[me�i$[����s�o�ᘨ�˸ nɜG-�ĨU�ycP�3.DB�li�;��hj���x7Z^�N�h������N3u{�:j�x�힞��#M&��jL P@_���� P��&��o8������9�����@Sz6�t7#O�ߋ �s}Yf�T���lmr����Z)'N��k�۞p����w\�Tȯ?�8`�O��i{wﭹW�[�r�� ��Q4F�׊���3m&L�=��h3����z~��#�\�l :�F,j@�� ʱ�wQT����8�"kJO���6�֚l����}���R�>ډK���]��y����&����p�}b��;N�1�m�r$�|��7�>e�@B�TM*-iH��g�D�)� E�m�|�ؘbҗ�a��Ҿ����t4���o���G��*oCN�rP���Q��@z,|?W[0�����:�n,jWiE��W��$~/�hp\��?��{(�0���+�Y8rΟ�+����>S-S����VN;�}�s?.����� w�9��˟<���Mq4�Wv'��{)0�1mB��V����W[�����8�/<� �%���wT^�5���b��)iM� pg�N�&ݝ��VO~�q���u���9� ����!��J27����$O-���! �:�%H��� ـ����y�ΠM=t{!S�� oK8������t<����è:a������[�����ա�H���~��w��Qz`�po�^ ����Q��n� �,uu�C�$ ^���,������8�#��:�6��e�|~���!�3�3.�\0��q��o�4`.|� ����y�Q�`~;�d�ׯ,��O�Zw�������`73�v�܋�<���Ȏ�� ـ4k��5�K�a�u�=9Yd��$>x�A�&�� j0� ���vF��� Y�|�y��� ~�6�@c��1vOp�Ig����4��l�OD���L����� R���c���j�_�uX6��3?nk��Wy�f;^*B� ��@�~a�`��Eu������+���6�L��.ü>��}y���}_�O�6�͐�:�YrG�X��kG�����l^w���~㒶sy��Iu�!� W ��X��N�7BV��O��!X�2����wvG�R�f�T#�����t�/?���%8�^�W�aT��G�cL�M���I��(J����1~�8�?aT ���]����AS�E��(��*E}� 2��#I/�׍qz��^t�̔���b�Yz4x���t�){ OH��+(E��A&�N�������XT��o��"�XC��'���)}�J�z�p� ��~5�}�^����+�6����w��c��Q�|Lp�d�H��}�(�.|����k��c4^�"�����Z?ȕ ��a<�L�!039C� �Eu�C�F�Ew�ç ;�n?�*o���B�8�bʝ���'#Rqf���M}7����]����s2tcS{�\icTx;�\��7K���P���ʇ Z O-��~��c>"��?�������P��E��O�8��@�8��G��Q�g�a�Վ���󁶠�䧘��_%#r�>�1�z�a��eb��qcPѵ��n���#L��� =��׀t� L�7�`��V���A{�C:�g���e@�w1 Xp3�c3�ġ����p��M"'-�@n4���fG��B3�DJ�8[Jo�ߐ���gK)ƛ��$���� ���8�3�����+���� �����6�ʻ���� ���S�kI�*KZlT _`���?��K����QK�d����B`�s}�>���`��*�>��,*@J�d�oF*����弝��O}�k��s��]��y�ߘ��c1G�V���<=�7��7����6�q�PT��tXԀ�!9*4�4Tހ3XΛex�46���Y��D ����� �BdemDa����\�_l,��G�/���֌7���Y�](�xTt^%�GE�����4�}bT���ڹ�����;Y)���B�Q��u��>J/J �⮶.�XԄ��j�ݳ�+E��d ��r�5�_D�1 ��o�� �B�x�΢�#���<��W�����8���R6�@g�M�.��� dr�D��>(otU��@x=��~v���2� ӣ�d�oBd��3�eO�6�㣷�����ݜ6��6Y��Qz`��S��{���\P�~z m5{J/L��1������<�e�ͅPu�b�]�ϔ���'������f�b� Zpw��c`"��i���BD@:)ִ�:�]��hv�E�w���T�l��P���"Ju�}��وV J��G6��. J/�Qgl߭�e�����@�z�Zev2u�)]կ�����7x���s�M�-<ɯ�c��r�v�����@��$�ޮ}lk���a���'����>x��O\�ZFu>�����ck#��&:��`�$�ai�>2Δ����l���oF[h��lE�ܺ�Πk:)���`�� $[6�����9�����kOw�\|���8}������ބ:��񶐕��I�A1/�=�2[�,�!��.}gN#�u����b��� ~��݊��}34q����d�E��Lc��$��"�[q�U�硬g^��%B �z���r�pJ�ru%v\h1Y�ne`ǥ:g���pQM~�^�Xi� ��`S�:V29.�P���V�?B�k�� AEvw%�_�9C�Q����wKekPؠ�\�;Io d�{ ߞo�c1eP����\� `����E=���@K<�Y���eڼ�J���w����{av�F�'�M�@/J��+9p���|]�����Iw &`��8���&M�hg��[�{��Xj��%��Ӓ�$��(����ʹN���<>�I���RY���K2�NPlL�ɀ)��&e����B+ь����( � �JTx���_?EZ� }@ 6�U���뙢ط�z��dWI�n` D����噥�[��uV��"�G&Ú����2g�}&m��?ċ�"����Om#��������� ��{�ON��"S�X��Ne��ysQ���@Fn��Vg���dX�~nj�]J�<�K]:��FW��b�������62�=��5f����JKw��bf�X�55��~J �%^����:�-�QIE��P��v�nZum� z � ~ə ���� ���ة����;�f��\v���g�8�1��f24;�V���ǔ�)����9���1\��c��v�/'Ƞ�w�������$�4�R-��t���� e�6�/�ġ �̕Ecy�J���u�B���<�W�ַ~�w[B1L۲�-JS΂�{���΃������A��20�c#��@ 0!1@AP"#2Q`$3V�%45a6�FRUq��� ����^7ׅ,$n�������+��F�`��2X'��0vM��p�L=������5��8������u�p~���.�`r�����\���O��,ư�0oS ��_�M�����l���4�kv\JSd���x���SW�<��Ae�IX����������$I���w�:S���y���›R��9�Q[���,�5�;�@]�%���u�@ *ro�lbI �� ��+���%m:�͇ZV�����u�̉����θau<�fc�.����{�4Ա� �Q����*�Sm��8\ujqs]{kN���)qO�y�_*dJ�b�7���yQqI&9�ԌK!�M}�R�;������S�T���1���i[U�ɵz�]��U)V�S6���3$K{�ߊ<�(� E]Զ[ǼENg�����'�\?#)Dkf��J���o��v���'�%ƞ�&K�u�!��b�35LX�Ϸ��63$K�a�;�9>,R��W��3�3� d�JeTYE.Mϧ��-�o�j3+y��y^�c�������VO�9NV\nd�1 ��!͕_)a�v;����թ�M�lWR1��)El��P;��yوÏ�u 3�k�5Pr6<�⒲l�!˞*��u־�n�!�l:����UNW ��%��Chx8vL'��X�@��*��)���̮��ˍ��� ���D-M�+J�U�kvK����+�x8��cY������?�Ԡ��~3mo��|�u@[XeY�C�\Kp�x8�oC�C�&����N�~3-H���� ��MX�s�u<`���~"WL��$8ξ��3���a�)|:@�m�\���^�`�@ҷ)�5p+��6���p�%i)P M���ngc�����#0Aruz���RL+xSS?���ʮ}()#�t��mˇ!��0}}y����<�e� �-ή�Ԩ��X������ MF���ԙ~l L.3���}�V뽺�v�����멬��Nl�)�2����^�Iq��a��M��qG��T�����c3#������3U�Ǎ���}��לS�|qa��ڃ�+���-��2�f����/��bz��ڐ�� �ݼ[2�ç����k�X�2�* �Z�d���J�G����M*9W���s{��w���T��x��y,�in�O�v��]���n����P�$�JB@=4�OTI�n��e�22a\����q�d���%�$��(���:���: /*�K[PR�fr\nڙdN���F�n�$�4�[�� U�zƶ����� �mʋ���,�ao�u 3�z� �x��Kn����\[��VFmbE;�_U��&V�Gg�]L�۪&#n%�$ɯ�dG���D�TI=�%+AB�Ru#��b4�1�»x�cs�YzڙJG��f��Il��d�eF'T� iA��T���uC�$����Y��H?����[!G`}���ͪ� �纤Hv\������j�Ex�K���!���OiƸ�Yj�+u-<���'q����uN�*�r\��+�]���<�wOZ.fp�ێ��,-*)V?j-kÊ#�`�r��dV����(�ݽBk�����G�ƛk�QmUڗe��Z���f}|����8�8��a���i��3'J�����~G_�^���d�8w������ R�`(�~�.��u���l�s+g�bv���W���lGc}��u���afE~1�Ue������Z�0�8�=e�� f@/�jqEKQQ�J��oN��J���W5~M>$6�Lt�;$ʳ{���^��6�{����v6���ķܰg�V�cnn �~z�x�«�,2�u�?cE+Ș�H؎�%�Za�)���X>uW�Tz�Nyo����s���FQƤ��$��*�&�LLXL)�1�" L��eO��ɟ�9=���:t��Z���c��Ž���Y?�ӭV�wv�~,Y��r�ۗ�|�y��GaF�����C�����.�+� ���v1���fήJ�����]�S��T��B��n5sW}y�$��~z�'�c ��8 ��� ,! �p��VN�S��N�N�q��y8z˱�A��4��*��'������2n<�s���^ǧ˭P�Jޮɏ�U�G�L�J�*#��<�V��t7�8����TĜ>��i}K%,���)[��z�21z ?�N�i�n1?T�I�R#��m-�����������������1����lA�`��fT5+��ܐ�c�q՝��ʐ��,���3�f2U�եmab��#ŠdQ�y>\��)�SLY����w#��.���ʑ�f��� ,"+�w�~�N�'�c�O�3F�������N<���)j��&��,-� �љ���֊�_�zS���TǦ����w�>��?�������n��U仆�V���e�����0���$�C�d���rP �m�׈e�Xm�Vu� �L��.�bֹ��� �[Դaզ���*��\y�8�Է:�Ez\�0�Kq�C b��̘��cө���Q��=0Y��s�N��S.���3.���O�o:���#���v7�[#߫ ��5�܎�L���Er4���9n��COWlG�^��0k�%<���ZB���aB_���������'=��{i�v�l�$�uC���mƎҝ{�c㱼�y]���W�i ��ߧc��m�H� m�"�"�����;Y�ߝ�Z�Ǔ�����:S#��|}�y�,/k�Ld� TA�(�AI$+I3��;Y*���Z��}|��ӧO��d�v��..#:n��f>�>���ȶI�TX��� 8��y����"d�R�|�)0���=���n4��6ⲑ�+��r<�O�܂~zh�z����7ܓ�HH�Ga롏���nCo�>������a ���~]���R���̲c?�6(�q�;5%� |�uj�~z8R=X��I�V=�|{v�Gj\gc��q����z�؋%M�ߍ����1y��#��@f^���^�>N�����#x#۹��6�Y~�?�dfPO��{��P�4��V��u1E1J �*|���%���JN��`eWu�zk M6���q t[�� ��g�G���v��WIG��u_ft����5�j�"�Y�:T��ɐ���*�;� e5���4����q$C��2d�}���� _S�L#m�Yp��O�.�C�;��c����Hi#֩%+) �Ӎ��ƲV���SYź��g |���tj��3�8���r|���V��1#;.SQ�A[���S������#���`n�+���$��$I �P\[�@�s��(�ED�z���P��])8�G#��0B��[ى��X�II�q<��9�~[Z멜�Z�⊔IWU&A>�P~�#��dp<�?����7���c��'~���5 ��+$���lx@�M�dm��n<=e�dyX��?{�|Aef ,|n3�<~z�ƃ�uۧ�����P��Y,�ӥQ�*g�#먙R�\���;T��i,��[9Qi歉����c>]9�� ��"�c��P�� �Md?٥��If�ت�u��k��/����F��9�c*9��Ǎ:�ØF���z�n*�@|I�ށ9����N3{'��[�'ͬ�Ҳ4��#}��!�V� Fu��,�,mTIk���v C�7v���B�6k�T9��1�*l� '~��ƞF��lU��'�M ����][ΩũJ_�{�i�I�n��$���L�� j��O�dx�����kza۪��#�E��Cl����x˘�o�����V���ɞ�ljr��)�/,�߬h�L��#��^��L�ф�,íMƁe�̩�NB�L�����iL����q�}��(��q��6IçJ$�W�E$��:������=#����(�K�B����zђ <��K(�N�۫K�w��^O{!����)�H���>x�������lx�?>Պ�+�>�W���,Ly!_�D���Ō�l���Q�!�[ �S����J��1��Ɛ�Y}��b,+�Lo�x�ɓ)����=�y�oh�@�꥟/��I��ѭ=��P�y9��� �ۍYӘ�e+�p�Jnϱ?V\SO%�(�t� ���=?MR�[Ș�����d�/ ��n�l��B�7j� ��!�;ӥ�/�[-���A�>�dN�sLj ��,ɪv��=1c�.SQ�O3�U���ƀ�ܽ�E����������̻��9G�ϷD�7(�}��Ävӌ\�y�_0[w ���<΍>����a_��[0+�L��F.�޺��f�>oN�T����q;���y\��bՃ��y�jH�<|q-eɏ�_?_9+P���Hp$�����[ux�K w�Mw��N�ی'$Y2�=��q���KB��P��~������Yul:�[<����F1�2�O���5=d����]Y�sw:���Ϯ���E��j,_Q��X��z`H1,#II ��d�wr��P˂@�ZJV����y$�\y�{}��^~���[:N����ߌ�U�������O��d�����ؾe��${p>G��3c���Ė�lʌ�� ת��[��`ϱ�-W����dg�I��ig2��� ��}s ��ؤ(%#sS@���~���3�X�nRG�~\jc3�v��ӍL��M[JB�T��s3}��j�Nʖ��W����;7��ç?=X�F=-�=����q�ߚ���#���='�c��7���ڑW�I(O+=:uxq�������������e2�zi+�kuG�R��������0�&e�n���iT^J����~\jy���p'dtG��s����O��3����9* �b#Ɋ�� p������[Bws�T�>d4�ۧs���nv�n���U���_�~,�v����ƜJ1��s�� �QIz��)�(lv8M���U=�;����56��G���s#�K���MP�=��LvyGd��}�VwWBF�'�à �?MH�U�g2�� ����!�p�7Q��j��ڴ����=��j�u��� Jn�A s���uM������e��Ɔ�Ҕ�!)'��8Ϣ�ٔ��ޝ(��Vp���צ֖d=�IC�J�Ǡ{q������kԭ�߸���i��@K����u�|�p=..�*+����x�����z[Aqġ#s2a�Ɗ���RR�)*HRsi�~�a &f��M��P����-K�L@��Z��Xy�'x�{}��Zm+���:�)�) IJ�-i�u���� ���ܒH��'�L(7�y�GӜq���� j��� 6ߌg1�g�o���,kر���tY�?W,���p���e���f�OQS��!K�۟cҒA�|ս�j�>��=⬒��˧L[�� �߿2JaB~R��u�:��Q�] �0H~���]�7��Ƽ�I���(}��cq '�ήET���q�?f�ab���ӥvr� �)o��-Q��_'����ᴎo��K������;��V���o��%���~OK ����*��b�f:���-ťIR��`B�5!RB@���ï�� �u �̯e\�_U�_������� g�ES��3�������QT��a����x����U<~�c?�*�#]�MW,[8O�a�x��]�1bC|踤�P��lw5V%�)�{t�<��d��5���0i�XSU��m:��Z�┵�i�"��1�^B�-��P�hJ��&)O��*�D��c�W��vM��)����}���P��ܗ-q����\mmζZ-l@�}��a��E�6��F�@��&Sg@���ݚ�M����� ȹ 4����#p�\H����dYDo�H���"��\��..R�B�H�z_�/5˘����6��KhJR��P�mƶi�m���3�,#c�co��q�a)*Pt����R�m�k�7x�D�E�\Y�閣_X�<���~�)���c[[�BP����6�Yq���S��0����%_����;��Àv�~�| VS؇ ��'O0��F0��\���U�-�d@�����7�SJ*z��3n��y��P����O���������m�~�P�3|Y��ʉr#�C�<�G~�.,! ���bqx���h~0=��!ǫ�jy����l�O,�[B��~��|9��ٱ����Xly�#�i�B��g%�S��������tˋ���e���ې��\[d�t)��.+u�|1 ������#�~Oj����hS�%��i.�~X���I�H�m��0n���c�1uE�q��cF�RF�o���7� �O�ꮧ� ���ۛ{��ʛi5�rw?׌#Qn�TW��~?y$��m\�\o����%W� ?=>S�N@�� �Ʈ���R����N�)�r"C�:��:����� �����#��qb��Y�. �6[��2K����2u�Ǧ�HYR��Q�MV��� �G�$��Q+.>�����nNH��q�^��� ����q��mM��V��D�+�-�#*�U�̒ ���p욳��u:�������IB���m���PV@O���r[b= �� ��1U�E��_Nm�yKbN�O���U�}�the�`�|6֮P>�\2�P�V���I�D�i�P�O;�9�r�mAHG�W�S]��J*�_�G��+kP�2����Ka�Z���H�'K�x�W�MZ%�O�YD�Rc+o��?�q��Ghm��d�S�oh�\�D�|:W������UA�Qc yT�q������~^�H��/��#p�CZ���T�I�1�ӏT����4��"�ČZ�����}��`w�#�*,ʹ�� ��0�i��課�Om�*�da��^gJ݅{���l�e9uF#T�ֲ��̲�ٞC"�q���ߍ ոޑ�o#�XZTp����@ o�8��(jd��xw�]�,f���`~�|,s��^����f�1���t��|��m�򸄭/ctr��5s��7�9Q�4�H1꠲BB@l9@���C�����+�wp�xu�£Yc�9��?`@#�o�mH�s2��)�=��2�.�l����jg�9$�Y�S�%*L������R�Y������7Z���,*=�䷘$�������arm�o�ϰ���UW.|�r�uf����IGw�t����Zwo��~5 ��YյhO+=8fF�)�W�7�L9lM�̘·Y���֘YLf�큹�pRF���99.A �"wz��=E\Z���'a� 2��Ǚ�#;�'}�G���*��l��^"q��+2FQ� hj��kŦ��${���ޮ-�T�٭cf�|�3#~�RJ����t��$b�(R��(����r���dx� >U b�&9,>���%E\� Ά�e�$��'�q't��*�א���ެ�b��-|d���SB�O�O��$�R+�H�)�܎�K��1m`;�J�2�Y~9��O�g8=vqD`K[�F)k�[���1m޼c��n���]s�k�z$@��)!I �x՝"v��9=�ZA=`Ɠi �:�E��)`7��vI��}d�YI�_ �o�:ob���o ���3Q��&D&�2=�� �Ά��;>�h����y.*ⅥS������Ӭ�+q&����j|UƧ����}���J0��WW< ۋS�)jQR�j���Ư��rN)�Gű�4Ѷ(�S)Ǣ�8��i��W52���No˓� ۍ%�5brOn�L�;�n��\G����=�^U�dI���8$�&���h��'���+�(������cȁ߫k�l��S^���cƗjԌE�ꭔ��gF���Ȓ��@���}O���*;e�v�WV���YJ\�]X'5��ղ�k�F��b 6R�o՜m��i N�i����>J����?��lPm�U��}>_Z&�KK��q�r��I�D�Չ~�q�3fL�:S�e>���E���-G���{L�6p�e,8��������QI��h��a�Xa��U�A'���ʂ���s�+טIjP�-��y�8ۈZ?J$��W�P� ��R�s�]��|�l(�ԓ��sƊi��o(��S0��Y� 8�T97.�����WiL��c�~�dxc�E|�2!�X�K�Ƙਫ਼�$((�6�~|d9u+�qd�^3�89��Y�6L�.I�����?���iI�q���9�)O/뚅����O���X��X�V��ZF[�یgQ�L��K1���RҖr@v�#��X�l��F���Нy�S�8�7�kF!A��sM���^rkp�jP�DyS$N���q��nxҍ!U�f�!eh�i�2�m���`�Y�I�9r�6� �TF���C}/�y�^���Η���5d�'��9A-��J��>{�_l+�`��A���[�'��յ�ϛ#w:݅�%��X�}�&�PSt�Q�"�-��\縵�/����$Ɨh�Xb�*�y��BS����;W�ջ_mc�����vt?2}1�;qS�d�d~u:2k5�2�R�~�z+|HE!)�Ǟl��7`��0�<�,�2*���Hl-��x�^����'_TV�gZA�'j� ^�2Ϊ��N7t�����?w�� �x1��f��Iz�C-Ȗ��K�^q�;���-W�DvT�7��8�Z�������� hK�(P:��Q- �8�n�Z���܃e貾�<�1�YT<�,�����"�6{/ �?�͟��|1�:�#g��W�>$����d��J��d�B��=��jf[��%rE^��il:��B���x���Sּ�1հ��,�=��*�7 fcG��#q� �eh?��2�7�����,�!7x��6�n�LC�4x��},Geǝ�tC.��vS �F�43��zz\��;QYC,6����~;RYS/6���|2���5���v��T��i����������mlv��������&� �nRh^ejR�LG�f���? �ۉҬܦƩ��|��Ȱ����>3����!v��i�ʯ�>�v��オ�X3e���_1z�Kȗ\<������!�8���V��]��?b�k41�Re��T�q��mz��TiOʦ�Z��Xq���L������q"+���2ۨ��8}�&N7XU7Ap�d�X��~�׿��&4e�o�F��� �H����O���č�c�� 懴�6���͉��+)��v;j��ݷ�� �UV�� i��� j���Y9GdÒJ1��詞�����V?h��l����l�cGs�ځ�������y�Ac�����\V3�? �� ܙg�>qH�S,�E�W�[�㺨�uch�⍸�O�}���a��>�q�6�n6����N6�q������N ! 1AQaq�0@����"2BRb�#Pr���3C`��Scst���$4D���%Td�� ?���N����a��3��m���C���w��������xA�m�q�m���m������$����4n淿t'��C"w��zU=D�\R+w�p+Y�T�&�պ@��ƃ��3ޯ?�Aﶂ��aŘ���@-�����Q�=���9D��ռ�ѻ@��M�V��P��܅�G5�f�Y<�u=,EC)�<�Fy'�"�&�չ�X~f��l�KԆV��?�� �W�N����=(� �;���{�r����ٌ�Y���h{�١������jW����P���Tc�����X�K�r��}���w�R��%��?���E��m�� �Y�q|����\lEE4���r���}�lsI�Y������f�$�=�d�yO����p�����yBj8jU�o�/�S��?�U��*������ˍ�0������u�q�m [�?f����a�� )Q�>����6#������� ?����0UQ����,IX���(6ڵ[�DI�MNލ�c&���υ�j\��X�R|,4��� j������T�hA�e��^���d���b<����n�� �즇�=!���3�^�`j�h�ȓr��jẕ�c�,ٞX����-����a�ﶔ���#�$��]w�O��Ӫ�1y%��L�Y<�wg#�ǝ�̗`�x�xa�t�w��»1���o7o5��>�m뭛C���Uƃߜ}�C���y1Xνm�F8�jI���]����H���ۺиE@I�i;r�8ӭ����V�F�Շ| ��&?�3|x�B�MuS�Ge�=Ӕ�#BE5G�����Y!z��_e��q�р/W>|-�Ci߇�t�1ޯќd�R3�u��g�=0 5��[?�#͏��q�cf���H��{ ?u�=?�?ǯ���}Z��z���hmΔ�BFTW�����<�q�(v� ��!��z���iW]*�J�V�z��gX֧A�q�&��/w���u�gYӘa���; �i=����g:��?2�dž6�ى�k�4�>�Pxs����}������G�9��3 ���)gG�R<>r h�$��'nc�h�P��Bj��J�ҧH� -��N1���N��?��~��}-q!=��_2hc�M��l�vY%UE�@|�v����M2�.Y[|y�"Eï��K�ZF,�ɯ?,q�?v�M 80jx�"�;�9vk�����+ ֧�� �ȺU��?�%�vcV��mA�6��Qg^M����A}�3�nl� QRN�l8�kkn�'�����(��M�7m9و�q���%ޟ���*h$Zk"��$�9��: �?U8�Sl��,,|ɒ��xH(ѷ����Gn�/Q�4�P��G�%��Ա8�N��!� �&�7�;���eKM7�4��9R/%����l�c>�x;������>��C�:�����t��h?aKX�bhe�ᜋ^�$�Iհ �hr7%F$�E��Fd���t��5���+�(M6�t����Ü�UU|zW�=a�Ts�Tg������dqP�Q����b'�m���1{|Y����X�N��b �P~��F^F:����k6�"�j!�� �I�r�`��1&�-$�Bevk:y���#yw��I0��x��=D�4��tU���P�ZH��ڠ底taP��6����b>�xa����Q�#� WeF��ŮNj�p�J* mQ�N����*I�-*�ȩ�F�g�3 �5��V�ʊ�ɮ�a��5F���O@{���NX��?����H�]3��1�Ri_u��������ѕ�� ����0��� F��~��:60�p�͈�S��qX#a�5>���`�o&+�<2�D����: �������ڝ�$�nP���*)�N�|y�Ej�F�5ټ�e���ihy�Z �>���k�bH�a�v��h�-#���!�Po=@k̆IEN��@��}Ll?j�O������߭�ʞ���Q|A07x���wt!xf���I2?Z��<ץ�T���cU�j��]��陎Ltl �}5�ϓ��$�,��O�mˊ�;�@O��jE��j(�ا,��LX���LO���Ц�90�O �.����a��nA���7������j4 ��W��_ٓ���zW�jcB������y՗+EM�)d���N�g6�y1_x��p�$Lv:��9�"z��p���ʙ$��^��JԼ*�ϭ����o���=x�Lj�6�J��u82�A�H�3$�ٕ@�=Vv�]�'�qEz�;I˼��)��=��ɯ���x �/�W(V���p�����$ �m�������u�����񶤑Oqˎ�T����r��㠚x�sr�GC��byp�G��1ߠ�w e�8�$⿄����/�M{*}��W�]˷.�CK\�ުx���/$�WPw���r� |i���&�}�{�X� �>��$-��l���?-z���g����lΆ���(F���h�vS*���b���߲ڡn,|)mrH[���a�3�ר�[1��3o_�U�3�TC�$��(�=�)0�kgP���� ��u�^=��4 �WYCҸ:��vQ�ר�X�à��tk�m,�t*��^�,�}D*� �"(�I��9R����>`�`��[~Q]�#af��i6l��8���6�:,s�s�N6�j"�A4���IuQ��6E,�GnH��zS�HO�uk�5$�I�4��ؤ�Q9�@��C����wp�BGv[]�u�Ov���0I4���\��y�����Q�Ѹ��~>Z��8�T��a��q�ޣ;z��a���/��S��I:�ܫ_�|������>=Z����8:�S��U�I�J��"IY���8%b8���H��:�QO�6�;7�I�S��J��ҌAά3��>c���E+&jf$eC+�z�;��V����� �r���ʺ������my�e���aQ�f&��6�ND��.:��NT�vm�<- u���ǝ\MvZY�N�NT��-A�>jr!S��n�O 1�3�Ns�%�3D@���`������ܟ 1�^c<���� �a�ɽ�̲�Xë#�w�|y�cW�=�9I*H8�p�^(4���՗�k��arOcW�tO�\�ƍR��8����'�K���I�Q�����?5�>[�}��yU�ײ -h��=��% q�ThG�2�)���"ו3]�!kB��*p�FDl�A���,�eEi�H�f�Ps�����5�H:�Փ~�H�0Dت�D�I����h�F3�������c��2���E��9�H��5�zԑ�ʚ�i�X�=:m�xg�hd(�v����׊�9iS��O��d@0ڽ���:�p�5�h-��t�&���X�q�ӕ,��ie�|���7A�2���O%P��E��htj��Y1��w�Ѓ!����  ���� ࢽ��My�7�\�a�@�ţ�J �4�Ȼ�F�@o�̒?4�wx��)��]�P��~�����u�����5�����7X ��9��^ܩ�U;Iꭆ 5 �������eK2�7(�{|��Y׎ �V��\"���Z�1� Z�����}��(�Ǝ"�1S���_�vE30>���p;� ΝD��%x�W�?W?v����o�^V�i�d��r[��/&>�~`�9Wh��y�;���R��� ;;ɮT��?����r$�g1�K����A��C��c��K��l:�'��3 c�ﳯ*"t8�~l��)���m��+U,z��`(�>yJ�?����h>��]��v��ЍG*�{`��;y]��I�T� ;c��NU�fo¾h���/$���|NS���1�S�"�H��V���T���4��uhǜ�]�v;���5�͠x��'C\�SBpl���h}�N����� A�Bx���%��ޭ�l��/����T��w�ʽ]D�=����K���ž�r㻠l4�S�O?=�k �M:� ��c�C�a�#ha���)�ѐxc�s���gP�iG��{+���x���Q���I= �� z��ԫ+ �8"�k�ñ�j=|����c ��y��CF��/��*9ж�h{ �?4�o� ��k�m�Q�N�x��;�Y��4膚�a�w?�6�>e]�����Q�r�:����g�,i"�����ԩA�*M�<�G��b�if��l^M��5� �Ҩ�{����6J��ZJ�����P�*�����Y���ݛu�_4�9�I8�7���������,^ToR���m4�H��?�N�S�ѕw��/S��甍�@�9H�S�T��t�ƻ���ʒU��*{Xs�@����f�����֒Li�K{H�w^���������Ϥm�tq���s� ���ք��f:��o~s��g�r��ט� �S�ѱC�e]�x���a��) ���(b-$(�j>�7q�B?ӕ�F��hV25r[7 Y� }L�R��}����*sg+��x�r�2�U=�*'WS��ZDW]�WǞ�<��叓���{�$�9Ou4��y�90-�1�'*D`�c�^o?(�9��u���ݐ��'PI&� f�Jݮ�������:wS����jfP1F:X �H�9dԯ���˝[�_54 �}*;@�ܨ�� ð�yn�T���?�ןd�#���4rG�ͨ��H�1�|-#���Mr�S3��G�3�����)�.᧏3v�z֑��r����$G"�`j �1t��x0<Ɔ�Wh6�y�6��,œ�Ga��gA����y��b��)��h�D��ß�_�m��ü �gG;��e�v��ݝ�nQ� ��C����-�*��o���y�a��M��I�>�<���]obD��"�:���G�A��-\%LT�8���c�)��+y76���o�Q�#*{�(F�⽕�y����=���rW�\p���۩�c���A���^e6��K������ʐ�cVf5$�'->���ՉN"���F�"�UQ@�f��Gb~��#�&�M=��8�ט�JNu9��D��[̤�s�o�~������ G��9T�tW^g5y$b��Y'��س�Ǵ�=��U-2 #�MC�t(�i� �lj�@Q 5�̣i�*�O����s�x�K�f��}\��M{E�V�{�υ��Ƈ�����);�H����I��fe�Lȣr�2��>��W�I�Ȃ6������i��k�� �5�YOxȺ����>��Y�f5'��|��H+��98pj�n�.O�y�������jY��~��i�w'������l�;�s�2��Y��:'lg�ꥴ)o#'Sa�a�K��Z� �m��}�`169�n���"���x��I ��*+� }F<��cГ���F�P�������ֹ*�PqX�x۩��,� ��N�� �4<-����%����:��7����W���u�`����� $�?�I��&����o��o��`v�>��P��"��l���4��5'�Z�gE���8���?��[�X�7(��.Q�-��*���ތL@̲����v��.5���[��=�t\+�CNܛ��,g�SQnH����}*F�G16���&:�t��4ُ"A��̣��$�b �|����#rs��a�����T�� ]�<�j��BS�('$�ɻ� �wP;�/�n��?�ݜ��x�F��yUn�~mL*-�������Xf�wd^�a�}��f�,=t�׵i�.2/wpN�Ep8�OР���•��R�FJ� 55TZ��T �ɭ�<��]��/�0�r�@�f��V��V����Nz�G��^���7hZi����k��3�,kN�e|�vg�1{9]_i��X5y7� 8e]�U����'�-2,���e"����]ot�I��Y_��n�(JҼ��1�O ]bXc���Nu�No��pS���Q_���_�?i�~�x h5d'�(qw52] ��'ޤ�q��o1�R!���`ywy�A4u���h<קy���\[~�4�\ X�Wt/� 6�����n�F�a8��f���z �3$�t(���q��q�x��^�XWeN'p<-v�!�{�(>ӽDP7��ո0�y)�e$ٕv�Ih'Q�EA�m*�H��RI��=:��� ���4牢) �%_iN�ݧ�l]� �Nt���G��H�L��� ɱ�g<���1V�,�J~�ٹ�"K��Q�� 9�HS�9�?@��k����r�;we݁�]I�!{ �@�G�[�"��`���J:�n]�{�cA�E����V��ʆ���#��U9�6����j�#Y�m\��q�e4h�B�7��C�������d<�?J����1g:ٳ���=Y���D�p�ц� ׈ǔ��1�]26؜oS�'��9�V�FVu�P�h�9�xc�oq�X��p�o�5��Ա5$�9W�V(�[Ak�aY錎qf;�'�[�|���b�6�Ck��)��#a#a˙��8���=äh�4��2��C��4tm^ �n'c���]GQ$[Wҿ��i���vN�{Fu ��1�gx��1┷���N�m��{j-,��x�� Ūm�ЧS�[�s���Gna���䑴�� x�p 8<������97�Q���ϴ�v�aϚG��Rt�Һ׈�f^\r��WH�JU�7Z���y)�vg=����n��4�_)y��D'y�6�]�c�5̪�\� �PF�k����&�c;��cq�$~T�7j ���nç]�<�g ":�to�t}�159�<�/�8������m�b�K#g'I'.W�����6��I/��>v��\�MN��g���m�A�yQL�4u�Lj�j9��#44�t��l^�}L����n��R��!��t��±]��r��h6ٍ>�yҏ�N��fU�� ���� Fm@�8}�/u��jb9������he:A�y�ծw��GpΧh�5����l}�3p468��)U��d��c����;Us/�֔�YX�1�O2��uq�s��`hwg�r~�{ R��mhN��؎*q 42�*th��>�#���E����#��Hv�O����q�}�����6�e��\�,Wk�#���X��b>��p}�դ��3���T5��†��6��[��@�P�y*n��|'f�֧>�lư΂�̺����SU�'*�q�p�_S�����M�� '��c�6�����m�� ySʨ;M��r���Ƌ�m�Kxo,���Gm�P��A�G�:��i��w�9�}M(�^�V��$ǒ�ѽ�9���|���� �a����J�SQ�a���r�B;����}���ٻ֢�2�%U���c�#�g���N�a�ݕ�'�v�[�OY'��3L�3�;,p�]@�S��{ls��X�'���c�jw�k'a�.��}�}&�� �dP�*�bK=ɍ!����;3n�gΊU�ߴmt�'*{,=SzfD� A��ko~�G�aoq�_mi}#�m�������P�Xhύ����mxǍ�΂���巿zf��Q���c���|kc�����?���W��Y�$���_Lv����l߶��c���`?����l�j�ݲˏ!V��6����U�Ђ(A���4y)H���p�Z_�x��>���e��R��$�/�`^'3qˏ�-&Q�=?��CFVR �D�fV�9��{�8g�������n�h�(P"��6�[�D���< E�����~0<@�`�G�6����Hг�cc�� �c�K.5��D��d�B���`?�XQ��2��ٿyqo&+�1^� DW�0�ꊩ���G�#��Q�nL3��c���������/��x ��1�1[y�x�პCW��C�c�UĨ80�m�e�4.{�m��u���I=��f�����0QRls9���f���������9���~f�����Ǩ��a�"@�8���ȁ�Q����#c�ic������G��$���G���r/$W�(��W���V�"��m�7�[m�A�m����bo��D� j����۳� l���^�k�h׽����� ��#� iXn�v��eT�k�a�^Y�4�BN��ĕ��0 !01@Q"2AaPq3BR������?���@4�Q�����T3,���㺠�W�[=JK�Ϟ���2�r^7��vc�:�9 �E�ߴ�w�S#d���Ix��u��:��Hp��9E!�� V 2;73|F��9Y���*ʬ�F��D����u&���y؟��^EA��A��(ɩ���^��GV:ݜDy�`��Jr29ܾ�㝉��[���E;Fzx��YG��U�e�Y�C���� ����v-tx����I�sם�Ę�q��Eb�+P\ :>�i�C'�;�����k|z�رn�y]�#ǿb��Q��������w�����(�r|ӹs��[�D��2v-%��@;�8<a���[\o[ϧw��I!��*0�krs)�[�J9^��ʜ��p1)� "��/_>��o��<1����A�E�y^�C��`�x1'ܣn�p��s`l���fQ��):�l����b>�Me�jH^?�kl3(�z:���1ŠK&?Q�~�{�ٺ�h�y���/�[��V�|6��}�KbX����mn[-��7�5q�94�������dm���c^���h� X��5��<�eޘ>G���-�}�دB�ޟ� ��|�rt�M��V+�]�c?�-#ڛ��^ǂ}���Lkr���O��u�>�-D�ry� D?:ޞ�U��ǜ�7�V��?瓮�"�#���r��չģVR;�n���/_� ؉v�ݶe5d�b9��/O��009�G���5n�W����JpA�*�r9�>�1��.[t���s�F���nQ� V 77R�]�ɫ8����_0<՜�IF�u(v��4��F�k�3��E)��N:��yڮe��P�`�1}�$WS��J�SQ�N�j�ٺ��޵�#l���ј(�5=��5�lǏmoW�v-�1����v,W�mn��߀$x�<����v�j(����c]��@#��1������Ǔ���o'��u+����;G�#�޸��v-lη��/(`i⣍Pm^���ԯ̾9Z��F��������n��1��� ��]�[��)�'������:�֪�W��FC����� �B9،!?���]��V��A�Վ�M��b�w��G F>_DȬ0¤�#�QR�[V��kz���m�w�"��9ZG�7'[��=�Q����j8R?�zf�\a�=��O�U����*oB�A�|G���2�54 �p��.w7� �� ��&������ξxGHp� B%��$g�����t�Џ򤵍z���HN�u�Я�-�'4��0��;_��3 !01"@AQa2Pq#3BR������?��ʩca��en��^��8���<�u#��m*08r��y�N"�<�Ѳ0��@\�p��� �����Kv�D��J8�Fҽ� �f�Y��-m�ybX�NP����}�!*8t(�OqѢ��Q�wW�K��ZD��Δ^e��!� ��B�K��p~�����e*l}z#9ң�k���q#�Ft�o��S�R����-�w�!�S���Ӥß|M�l޶V��!eˈ�8Y���c�ЮM2��tk���� ������J�fS����Ö*i/2�����n]�k�\���|4yX�8��U�P.���Ы[���l��@"�t�<������5�lF���vU�����W��W��;�b�cД^6[#7@vU�xgZv��F�6��Q,K�v��� �+Ъ��n��Ǣ��Ft���8��0��c�@�!�Zq s�v�t�;#](B��-�nῃ~���3g������5�J�%���O������n�kB�ĺ�.r��+���#�N$?�q�/�s�6��p��a����a��J/��M�8��6�ܰ"�*������ɗud"\w���aT(����[��F��U՛����RT�b���n�*��6���O��SJ�.�ij<�v�MT��R\c��5l�sZB>F��<7�;EA��{��E���Ö��1U/�#��d1�a�n.1ě����0�ʾR�h��|�R��Ao�3�m3 ��%�� ���28Q� ��y��φ���H�To�7�lW>����#i`�q���c����a��� �m,B�-j����݋�'mR1Ήt�>��V��p���s�0IbI�C.���1R�ea�����]H�6����������4B>��o��](��$B���m�����a�!=��?�B� K�Ǿ+�Ծ"�n���K��*��+��[T#�{E�J�S����Q�����s�5�:�U�\wĐ�f�3����܆&�)����I���Ԇw��E T�lrTf6Q|R�h:��[K�� �z��c֧�G�C��%\��_�a�84��HcO�bi��ؖV��7H �)*ģK~Xhչ0��4?�0��� �E<���}3���#���u�?�� ��|g�S�6ꊤ�|�I#Hڛ� �ա��w�X��9��7���Ŀ%�SL��y6č��|�F�a 8���b��$�sק�h���b9RAu7�˨p�Č�_\*w��묦��F ����4D~�f����|(�"m���NK��i�S�>�$d7SlA��/�²����SL��|6N�}���S�˯���g��]6��; �#�.��<���q'Q�1|KQ$�����񛩶"�$r�b:���N8�w@��8$�� �AjfG|~�9F ���Y��ʺ��Bwؒ������M:I岎�G��`s�YV5����6��A �b:�W���G�q%l�����F��H���7�������Fsv7��k�� 403WebShell
403Webshell
Server IP : 104.21.45.146  /  Your IP : 172.69.130.107
Web Server : Apache/2.4.52 (Ubuntu)
System : Linux ip-172-31-19-221 6.8.0-1029-aws #31~22.04.1-Ubuntu SMP Thu Apr 24 21:16:18 UTC 2025 x86_64
User : www-data ( 33)
PHP Version : 8.1.28
Disable Function : NONE
MySQL : OFF  |  cURL : ON  |  WGET : ON  |  Perl : ON  |  Python : OFF  |  Sudo : ON  |  Pkexec : ON
Directory :  /efsdata/scitechnol.com/httpdocs/submission/uploads/

Upload File :
current_dir [ Writeable ] document_root [ Writeable ]

 

Command :


[ Back ]     

Current File : /efsdata/scitechnol.com/httpdocs/submission/uploads/1990-0-Manuscript-2014-05-30.doc
��ࡱ�>��	WY����TUV������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������	��o�bjbj$$	.�F|F|��+�������VV������������8���T�XX, t�(�(�(�(�)
�)�)[W]W]W]W]W]W]W$pZ�"]Z�WQ��)�)�)�)�)�W���(�(��W�4�4�4�)���(��([W�4�)[W�4�4-7y7�(�����f�)(|������2<E7GW�W0XM7,|]�3�|]y7y7|]��J��)�)�4�)�)�)�)�)�W�We4��)�)�)X�)�)�)�)��������������������������������������������������������������������|]�)�)�)�)�)�)�)�)�)V v:	May 3th, 2014
Outcomes in HIV-HBV-co-Infected Patients in the Tenofovir Era are Greatly Affected by Immune Suppression 
Andrew J. Huang, MS-III1, Marina N��ez, M.D., Ph.D. 2
1Wake Forest University School of Medicine; 2Division on Infectious Disease, Department on Internal Medicine, Wake Forest University Health Sciences 
Winston-Salem, North Carolina, USA
Running head: HIV-HBV-co-Infection Outcomes 

Key words: chronic hepatitis B, HIV infection, outcomes

Word Count: manuscript 3,206; abstract 249

Figures: 3; tables: 2

Correspondence: 
Marina Nunez, MD, PhD
Wake Forest University Health Sciences
Department of Internal Medicine, Section on Infectious Diseases
Medical Center Boulevard
Winston-Salem, NC� 27157, USA
Phone:� 336-716-4512; Fax: 336-716-3825
Email: mnunez@wakehealth.edu	

Funding source: This research has been possible thanks to the 2012 Medical student summer Research training Program, supported through grants from the National Institutes of Health, Wake forest University school of medicine and private gifts.

Abstract
Objectives: HIV patients have higher mortality when HBV-coinfected. With potent HAART and use of tenofovir outcomes may improve. Our objective was to determine the clinical and virological outcomes of a HIV-HBV-co-infected cohort at our center since tenofovir became available.
Methods: We retrospectively studied all HIV-HBV-coinfected adults followed between 2002 and 2012 for e"3 months. Outcome measurements included HBVDNA suppression, HBeAg and HBsAg clearance, cirrhosis diagnosis, development of liver complications, and overall and liver-related mortality. Predicting factors were assessed with log Rank test and logistic regression. 
Results: Median time of follow-up of the 99 patients included was 5 years. Undetectable HBV DNA and HBsAg loss was achieved by 65% and 18%, respectively. Overall and liver-related mortality rates were 4.58 and 0.91 per 100 person-years, respectively. Most patients died of causes unrelated to the liver. Four patients died from hepatocellular carcinoma (HCC) and one, HCV-co-infected, from liver failure. Higher CD4 counts at last follow-up were associated with HBV suppression [OR 1.004 (95% CI 1.001-1.006); p=.007], HBeAg loss [OR 1.003 (95% CI 1-1.005); p=.02], HBsAg loss [> 700 CD4: OR 3.80 (95% CI 1.06-13.58); p=.04] and survival [OR .994 (95% CI 0.990-0.997); p<.0001]. HCV-coinfection was associated with higher overall mortality [OR 7.74 (95% CI 1.47-40.81); p=.02]. 
Conclusions: Mortality was high and most often unrelated to liver disease in this HIV-HBV-coinfected cohort treated predominantly with tenofovir-containing HAART. Optimal CD4 counts predicted survival and the achievement of HBV virological end-points. Tenofovir prevented liver decompensation but not HCC, which was the predominant cause of liver deaths.


Introduction
	Soon after the AIDS epidemics began, it became apparent that HIV patients co-infected with HBV had a higher mortality risk [1]. A negative effect of the HIV on HBV-related liver disease was also identified. Cirrhosis was more common and mortality higher in HIV-HBV-coinfected compared to HBV monoinfected subjects [1,2]. Lamivudine, which was the first antiretroviral drug with activity also against HBV provided a mild reduction in liver-related mortality in HIV-HBV-coinfected subjects, although still remained high [3,4]. 
With the widespread use of tenofovir as part of HIV treatment, a new era began in the management of HBV, as it proved to be a more potent HBV inhibitor [5]. Tenofovir provides much more effective suppression of HBV replication without selecting resistance mutations [6-13]. However, complete suppression of HBV may take a long time or even never be achieved in patients with high levels of replication. The duration and degree of HBV suppression needed to prevent liver disease progression and liver complications in HIV-HBV-coinfection have not been well established. Short-term data from Africa suggest a positive effect of tenofovir on mortality in HIV-HBV-coinfected patients [14]. However, there is limited data in other settings. The objective of the present study was to determine the clinical and virological outcomes of a HIV-HBV-co-infected cohort at a tertiary center since tenofovir became available. The ultimate goal is to identify areas for potential intervention to increase survival in this population.
Methods
	We performed a retrospective and longitudinal cohort study based on a chart review of adult patients with HIV and HBV co-infection seen in the HIV Clinic at Wake Forest University Baptist Medical Center (WFUBMC) between 2002 and 2012. Data from this cohort have been previously published, with information obtained up to 2008 [10]. To be included in the study, subjects had to have with chronic hepatitis B virus (HBV) infection defined as HBV surface antigen (HBsAg) or detectable HBV DNA for a span of at least 6 months, HIV infection defined as positive HIV antibody confirmed by western blot, and a minimum follow-up of three months. 
	Data collected included (1) Demographics: age, sex, ethnicity and primary HIV risk factor; (2) Laboratory data: serum HBV DNA, HBV e-antigen (HBeAg), serum HIV RNA, alanine aminotransferase (ALT) levels and CD4+ lymphocyte counts at baseline and during follow-up, hepatitis C virus (HCV) antibody, with HCV RNA if antibody was positive; (3) Clinical data: time of follow-up, HBV treatment history, comorbidities, self-reported alcohol use [none/ moderate (<50 g/day)/ severe (>50 g/day)], self-reported adherence to HAART (suboptimal defined as <90% of doses), compliance with follow-up (�poor� defined as < 2 visits/year), imaging liver studies (liver ultrasound, CT scan, or MRI), history of liver decompensation (defined as ascites, encephalopathy, jaundice, or gastrointestinal bleeding), diagnosis of cirrhosis and of hepatocellular carcinoma, and death occurrence with its cause. The cause of death was obtained from reports in the chart, with verification of each case by reviewing the medical records). The diagnosis of cirrhosis was made through clinical findings which include liver image studies and presence of thrombocytopenia, portal hypertension, poor liver synthetic function or ascites.
	Time of follow-up was counted since 2002 or since the first visit to our center if it occurred after 2002. HBV baseline data refer to the time when patients initiated HBV-active antiretroviral treatment. HIV RNA, CD4+ lymphocyte counts and ALT levels were obtained at approximately three months intervals coinciding with clinic visits.  However, HBV data were not obtained at predetermined time points but as dictated by HIV care providers. CD4+ lymphocyte counts were measured by flow cytometry. HIV RNA levels were measured by PCR (lower limit of detection 400 copies/mL until June of 2000, and 50 copies/mL thereafter.)  HBV DNA levels were measured by PCR (measured in pg/mL until 2004; lower limit of detection <0.01 pg/mL; 1 pg = approximately 150,000 copies) and in IU/mL since 2005 (lower limit of detection <100IU/mL until 2011, and <20 IU/mL currently).  Serum HCV RNA was measured by quantitative PCR.
Statistical analyses. Outcome measurements included DNA suppression, HBeAg and HBsAg clearance, diagnosis of cirrhosis, development of liver complications, and overall and liver-related mortality. Continuous variables are expressed as median (interquartile range, IQR) and categorical variables as absolute numbers (percentage). Chi-square and t tests were used to compare categorical and continuous variables among groups, respectively. Logistic regression was used to identify factors associated with the outcomes. Variables analyzed for association with virological outcomes include age, sex, baseline parameters (HBV DNA levels, HBeAg status, ALT levels and CD4 counts), time to follow-up, HIV suppression on HAART, CD4 counts at last visit and changes during follow-up, duration of tenofovir treatment, self-reported adherence to therapy, and HCV-coinfection. Besides the above, variables analyzed for association with clinical outcomes include prior use of lamivudine without tenofovir, achievement of undetectable HBV DNA during follow-up, HBeAg or HBsAg loss during follow-up, ALT levels during follow-up and history of alcohol use. Survival estimates are expressed as cumulative proportion of surviving at the specific time point and as incidence rate. For the survival analysis, data were censored at the date of the respective endpoint, when the last information about survival and clinical status was available. The bivariate survival analysis was performed using the method of Kaplan-Meier. Curves were compared by the log rank test. Differences were considered to be significant with p values <.05. Data were analyzed using IBM SPSS Statistics Version 21.0 software package (IBM, Armonk, New York).

Results
Ninety nine HIV-HBV-coinfected patients met the specified criteria and were included in the study. Of them, 52 had positive HBeAg, 17 had negative HBeAg, and 30 had an unknown HBeAg status prior to initiation of HBV-active HAART. The characteristics of the patients are summarized in Table 1. Baseline HBVDNA was not available for 38 (38%) patients. Table 2 records the clinical and virological outcomes of the patients. They were followed up for a median time of 5 years and received HBV-active HAART for a median duration of 3 years. Ninety patients were treated with a tenofovir based therapy. Out of the 9 who did not receive tenofovir, three received lamivudine as part of their HAART (two of them had chronic kidney disease), and 6 did had not initiated HAART at last follow-up.
Virological outcome
HBV DNA suppression
All patients. Undetectable HBV DNA was achieved at least once during follow-up in 65% of patients. As depicted in figure 1, CD4 lymphocyte count e" 400 cells/mm3 at last follow-up (figure 1a; Log Rank test, p=.001), negative HBeAg at baseline (figure 1b; Log Rank test, p<.0001) and self-reported optimal adherence to HAART (figure 1c; Log Rank test, p=0.02) favored achievement of HBV suppression. Other factors associated with undetectable HBV DNA were age >45 [OR 2.89 (95% CI 1.25-6.68); p=0.01], well controlled HIV (defined as undetectable HIV RNA levels for >80% time of follow-up) [OR 3.33 (95% CI 1.28-8.70); p=0.01], higher nadir CD4 counts [OR 1.004 (95% CI 1.001-1.007); p=0.009], and greater CD4 gains on HAART [OR 1.004 (95% CI 1.001-1.007); p=0.003]. In the final multivariate analysis model, which included only 70 patients as HBeAg status was unknown in the remaining, baseline HBeAg status tended to prevent HBVDNA suppression [OR 0.20 (95%CI 0.04-1.03); p=0.05], while higher CD4 counts at last follow-up was associated with undetectable HBV DNA [OR 1.004 (95%CI 1.001-1.006); p=0.007]. Of note, while patients with well controlled HIV replication during follow-up were more likely to achieve undetectable HBV DNA [OR 6.87 (95%CI. 2.53-18.71); p<0.0001], it was not a guarantee of HBV suppression. Thus, out of 37 patients who had undetectable HIV for at least three years, 8 (22%) never achieved HBV DNA suppression. All of them had positive HBeAg or high HBVDNA levels at baseline. 

HBeAg-positive subjects. Out of the 52 HIV-HBV coinfected patients with known positive HBeAg at baseline, 51 received tenofovir with or without emtricitabine and 1 lamivudine. Thirty one (61%) achieved undetectable HBV titers at least once during follow-up after tenofovir-based treatment was initiated. In univariate analysis, factors associated with achievement of undetectable HBV DNA were higher CD4 counts as measured by absolute count at last follow-up and by cell increases increase during HAART, well controlled HIV and self-reported optimal adherence to HAART. In multivariate analysis, only self-reported optimal adherence to HAART [OR 4.3 (95% CI 1.01- 18.22); p=0.04] predicted HBVDNA suppression. 
HBeAg clearance
HBeAg loss occurred in 19 out of 52 (36.5%) HIV-HBV-co-infected patients with known positive HBeAg at baseline. In logistic regression analysis, higher CD4 counts at last follow-up [OR 1.003 (95% CI 1-1.005); p=0.02] and CD4 gains on HAART [OR 1.004 (95% CI 1.001-1.007); p=0.02] were associated with HBeAg clearance. 
HBsAg clearance
Eighteen patients (18%) lost the HBsAg during follow-up. However, 3 of them had reverse HBsAg seroconversion thereafter. HBsAg loss was comparable between patients with positive and negative HBeAg at baseline. Having CD4 count >700 cells/mm3 at last visit was associated with negative HBsAg [OR 4.15 (95%CI 1.15-14.98); p=0.03]. 
Liver-related morbidity
Fifteen patients (15%) were diagnosed with cirrhosis during follow-up. Two of them were also HCV-co-infected, and they eventually died. Univariate and multivariate analyses identified ALT elevation during follow-up (having ALT level greater than two times the upper normal limit (>60U/L for males and >38U/L for females) for at least 4 years) as only factor associated with the development of cirrhosis [OR 6.4 (95% CI 1.73-23.47); p=0.005], while HBsAg loss was the only protective factor [OR 4.81 (95%CI 1.28-18.002); p=0.02]. 
Liver-related complications in patients diagnosed with cirrhosis occurred in 6 patients. One patient, with long history of non-compliance had recurrent variceal hemorrhage and is currently alive. Another patient, HCV-co-infected, developed liver failure and died. The remaining four patients were diagnosed with HCC and eventually died.
Mortality
Overall mortality
A total of 25 (25%) patients died during follow-up. The mortality rate was 4.58 deaths per 100 patient-years. Figure 2 depicts overall and liver-related mortality curves. Most deaths occurred within the first 5 years of follow-up. The survival was 75% at 5 years and 61% at 10 years. The causes of death are summarized in Table 2. Most patients died of causes unrelated to the liver, mostly due to opportunistic infections, followed by malignancies (esophagus, recto-sigmoid, head/face/neck, pancreas, and squamous carcinoma of undetermined origin, one case each). Seven of the 15 patients diagnosed with cirrhosis died during follow-up, but in 2 cases it was not due to liver causes.
HCV-coinfection was associated with significantly worse survival (p =.002) (figure 3a).  Thus, 7 out of 11 patients with hepatitis C co-infection died during follow-up, 3 from HIV-related causes, 2 from non-hepatic neoplasms, and 2 from liver related causes (one from HCC and one from liver failure). Besides HCV-coinfection, univariate analysis identified also lower CD4 counts measured at baseline and last follow-up, smaller CD4 gains on HAART, higher HIVRNA levels at baseline and lack of HBV DNA suppression during follow-up as factors associated with overall mortality. Having a CD4 count >400 cells/mm3 at last follow-up (p<.001) predicted survival (figure 3b). In multivariate analysis HCV-co-infection was the only predictor of mortality [OR 7.74 (95% CI 1.47-40.81); p=0.02], and higher CD4 counts at last visit was the only predictor of survival [OR .994 (95% CI 0.990-0.997); p<0.0001]. 
Liver related mortality
Survival curve from liver-related causes is depicted in figure 2. Five (5%) patients died from liver-related causes during follow-up. The liver-related mortality rate was 0.91 per 100 patient-years. The most frequent cause of liver-related death was HCC, which occurred in 4 cases, while only one patient died from liver failure. Two patients were also infected with HCV: one died from HCC, and the other from liver failure. The 4 patients who died from HCC were male and had HCC diagnosed at ages ranging from 50 to 58. Two of them were diagnosed with HCC in 2007, one in 2008, and 1 in 2011. CD4+ lymphocyte counts ranged between 240 and 720 cells/mm3. All of them had received prolonged treatment with tenofovir (3-6 years) and had achieved undetectable HBVDNA during follow-up (for 1-3 years). One had negative HBeAg at baseline and three positive but one lost HBeAg during follow-up. However, transaminases remained elevated throughout follow-up in all cases. All patients had history of alcohol use.
Discussion
	In this cohort of HIV-HBV-coinfected patients with advanced HIV from a single institution, predominantly treated with tenofovir-containing HAART, and with one of the longest follow-up published to date, overall mortality remained high and was most often attributable to immunosuppression. This suggests that, as for any HIV-infected patient, avoiding CD4 lymphopenia through HIV control is paramount to improve survival in this population. Maintaining optimal CD4 counts did also help to achieve HBV virological end-points in our study. In addition, we showed that HBV suppression requires a higher level of adherence to treatment compared to HIV, especially with very high baseline HBVDNA levels. However, tenofovir appears to confer some benefit over liver disease even with more modest HBV responses, as liver decompensation was rare despite more than one third of patients never achieving undetectable HBV DNA. On the contrary, HCC was not fully prevented as it was the predominant cause of liver-related mortality and it occurred despite having achieved HBV suppression. Of note, HCV and/or alcohol history were present in all liver-related deaths, suggesting that to decrease liver-related mortality in this population, besides treating HBV other factors contributing to hepatic disease need to be addressed. 
	Consistent with other reports, HBV suppression was achieved more often and earlier in HBeAg-negative patients compared to those with positive antigen [12,13,15,16]. It was among those HBeAg+ patients that optimal compliance with treatment, but not HIV suppression, was identified as factor predicting HBV DNA suppression, in support of a prior report [16]. This suggests that HBV is less forgiving than HIV, requiring higher levels of adherence to treatment. Most importantly, our data suggest an important role for immune restoration in the achievement of all virological end-points. The importance of optimal CD4 counts to attain undetectable HBV DNA and to achieve greater declines of quantitative serum HBsAg has been previously reported [6,16,17]. We also showed that higher CD4 counts increase the likelihood of eliminating the HBe and HBs antigens. Significant CD4 gains with HAART in a population with advanced HIV disease at the time of HAART initiation might explain the high incidence of HBsAg loss in our cohort compared to prior reports in HIV-HBV-co-infected and HBV-monoinfected patients [11,12,16-22].  

The proportion of patients diagnosed with cirrhosis during follow-up was within the range of prior reports [2,8,11,12,18,23,24]. The incidence of cirrhosis was likely underestimated given the retrospective mature of our study and inconsistent ultrasound surveillance. Supporting results from a prior study, elevated ALT was associated with a diagnosis of cirrhosis during follow-up [23]. HBsAg loss was identified as factor protecting from being diagnosed with cirrhosis in our study. Liver decompensation was rare in our cohort, in line with results from another long-term study on tenofovir use among HIV-HBV-co-infected patients [12]. Interestingly, less patients achieved undetectable HBVDNA in our cohort compared to the aforementioned study, suggesting that tenofovir may provide histological benefit even without complete HBV suppression.
	The overall mortality rate in this study is among the highests reported in HIV-HBV-coinfected patients [1,23,25-27]. Deaths were most often due to non-hepatic causes, primarily due to opportunistic infections, and CD4 counts at follow-up were the strongest predictor of mortality despite a majority of patients being on HAART. A predominance of AIDS-related mortality among HBV-coinfected patients has been reported by two multicenter cohorts, from Europe and USA [25,26]. This is despite the consistent finding in multiple studies that HBV co-infection does not compromise the virological and immunological response to HAART [25-29]. The high AIDS-related death rate in our study could be explained by the advanced HIV disease and the often poor adherence to HAART and to follow-up. However, a possible effect of HBV on HIV disease cannot be completely ruled out. Our findings suggest that emphasis should be placed on the importance of HAART and of preserving or achieving optimal CD4 counts, to prevent opportunistic infections and to improve the virological response to HBV treatment. 
The other factor that greatly affected mortality in our study was HCV-coinfection. Although the mortality of the HIV-HBV-HCV subgroup was very high and contributed to a great extent to the liver-related mortality, HCV-co-infected patients most often died from non-hepatic causes. Confounding factors such as smoking, illicit drug use and psychiatric disease, often present in patients with HCV infection might have contributed to the high mortality. Therefore, these patients with triple infection constitute the group at highest risk of death and require multidisciplinary care.
There is scarce information on mortality attributed to liver disease among HIV-HBV-coinfected patients. Limited data suggest that liver-mortality rates were higher during the early HAART era with less frequent or shorter exposure to tenofovir (1.4 to 2.2 per 100 patient-years) [1,24,26]. Two other studies which reported lower liver-related mortality rate (0.7 per 100 patient-years), were not comparable given the younger patient�s age, which averaged mid 30�s, when liver complications are still infrequent [23,25]. Liver-related mortality in our cohort was low and comparable to a recent report with similar time of follow-up [12]. All in all, these data suggest that current HAART regimens relying on tenofovir are more effective than early HAART combinations at preventing liver complications as previous reports from underdeveloped countries had indicated [14,30]. 
Combining HCC and non-hepatic cancers, 36% of all deaths (9/25) were due to non-AIDS-related cancers. This supports prior reports of increasing proportion of lethal non-AIDS-related cancers in an aging HIV population [31]. While tenofovir appears to have prevented liver decompensation to a great extent in our population, it did not fully protect from the development of HCC, which was the predominant cause of liver-related deaths in our cohort. There were no survivors among patients diagnosed with HCC, supporting prior data which suggest worse outcome in HIV-infected patients with HCC compared to their HIV negative counterparts [32]. This is likely due to a number of reasons including too advanced disease at presentation, curative therapy offered less frequently, and no widespread use of liver transplantation [33-35]. The risk of HCC in patients with hepatitis B correlates with HBV DNA levels, and anti-HBV therapy appears to decrease the incidence of HCC in HBV monoinfection, although HCC still occurs in some patients with virologic suppression [36-39]. Earlier treatment and more prolonged HBV suppression may be needed to prevent HCC development. As HCC occurs more frequently in patients with cirrhosis and this can be prevented and partially reversed by prolonged antiviral therapy, with potent first line HBV therapy, a major contributory factor for the development of HCC can be acted upon [22,39,40-42].  
Limitations of our study include incomplete data given the retrospective design, and the frequent non-adherence to follow-up of our patients. While the demographics of our cohort are very similar to HIV-HBV coinfected individuals of U.S. metropolitan areas [43], it differs from the world�s HIV-HBV population, and therefore our results may not be applicable to other settings. 
In summary, mortality was high and most often unrelated to liver disease in this HIV-HBV-coinfected cohort with advanced HIV disease treated predominantly with tenofovir-containing HAART. Optimal CD4 counts not only predicted survival but also the achievement of HBV virological end-points. Liver-related mortality rate was low, confirming the positive effect of tenofovir on liver disease. Nevertheless, tenofovir use prevented liver decompensation but not HCC, which was the predominant cause of liver-related deaths in this cohort. 














References
Thio CL, Seaberg EC, Skolasky R, Jr.,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Phair%20J%5BAuthor%5D&cauthor=true&cauthor_uid=12493258" Phair J,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Visscher%20B%5BAuthor%5D&cauthor=true&cauthor_uid=12493258" Visscher B,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Mu%C3%B1oz%20A%5BAuthor%5D&cauthor=true&cauthor_uid=12493258" Mu�oz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-1926.
Colin JF, Cazals-Hatem D, Loriot MA, Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29:1306-1310.
Puoti M, Cozzi-Lepri A, Paraninfo G, Arici C, Moller NF, Lundgren JD, et al.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/16964824" Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. Antivir Ther. 2006;11(5):567-74. Erratum in: Antivir Ther 2006; 11:831. 
Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIV infected patients. Clin Infect Dis 2004; 38:1159�1166.
 HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=N%C3%BA%C3%B1ez%20M%5BAuthor%5D&cauthor=true&cauthor_uid=12441815" N��ez M,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=P%C3%A9rez-Olmeda%20M%5BAuthor%5D&cauthor=true&cauthor_uid=12441815" P�rez-Olmeda M,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=D%C3%ADaz%20B%5BAuthor%5D&cauthor=true&cauthor_uid=12441815" D�az B,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=R%C3%ADos%20P%5BAuthor%5D&cauthor=true&cauthor_uid=12441815" R�os P,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Gonz%C3%A1lez-Lahoz%20J%5BAuthor%5D&cauthor=true&cauthor_uid=12441815" Gonz�lez-Lahoz J,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Soriano%20V%5BAuthor%5D&cauthor=true&cauthor_uid=12441815" Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/12441815" \o "AIDS (London, England)." AIDS  2002; 16:2352-4.
N��ez M, Ramos B, D�az-Poll�n B,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Camino%20N%5BAuthor%5D&cauthor=true&cauthor_uid=16989608" Camino N,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Mart%C3%ADn-Carbonero%20L%5BAuthor%5D&cauthor=true&cauthor_uid=16989608" Mart�n-Carbonero L,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Barreiro%20P%5BAuthor%5D&cauthor=true&cauthor_uid=16989608" Barreiro P, et al.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/16989608" Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy. AIDS Res Hum Retroviruses 2006; 22:842-8.
Miailhes P, Trabaud MA, Pradat P, Lebouch� B, Chevallier M, Chevallier P, et al.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/17682999" Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis 2007; 45:624-32.
Sheng WH, Kao JH, Chen PJ, Huang LM, Chang SY, Sun HY, et al.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/17918088" Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis 2007; 45:1221-9.
Matthews GV, Seaberg E, Dore GJ,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Bowden%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23315316" Bowden S,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Dore%20GJ%5BAuthor%5D&cauthor=true&cauthor_uid=23315316" Dore GJ,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Lewin%20SR%5BAuthor%5D&cauthor=true&cauthor_uid=23315316" Lewin SR, et al.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/19584701" Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS 2009; 23:1707-15.
Lee T, N��ez M.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/19632954" Longer duration of HBV-active antiretroviral therapy is linked to favorable virological outcome in HIV-HBV co-infected patients. HIV Clin Trials 2009; 10:153-9.
Piroth L, Pol S, Lacombe K, Miailhes P, Rami A, Rey D, et al.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/20800920" Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study. J Hepatol 2010; 53:1006-12.
de Vries-Sluijs TE, Reijnders JG, Hansen BE, Zaaijer HL, Prins JM, Pas SD, et al.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/20801123" Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology 2010; 139:1934-41.
Mendes-Correa MC, Pinho JR, Gomes-Gouvea MS, da Silva AC, Guastini CF, Martins LG, et al.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/21933423" Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil. BMC Infect Dis 2011; 11:247.
Hawkins C, Christian B, Ye J,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Nagu%20T%5BAuthor%5D&cauthor=true&cauthor_uid=23196935" Nagu T,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Aris%20E%5BAuthor%5D&cauthor=true&cauthor_uid=23196935" Aris E,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Chalamilla%20G%5BAuthor%5D&cauthor=true&cauthor_uid=23196935" Chalamilla G, et al.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/23196935" Prevalence of hepatitis B co-infection and response to antiretroviral therapy among HIV-infected patients in Tanzania. AIDS 2013; 27:919-27. 
Childs K, Joshi D, Byrne R,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Bruce%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23435302" Bruce M,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Carey%20I%5BAuthor%5D&cauthor=true&cauthor_uid=23435302" Carey I,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Agarwal%20K%5BAuthor%5D&cauthor=true&cauthor_uid=23435302" Agarwal K, et al.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/23435302" Tenofovir based combination therapy for HIV/HBV co-infection: Factors associated with a partial HBV virological response in patients with undetectable HIV viraemia. AIDS 2013; 27:1443-1448
Matthews GV, Seaberg EC, Avihingsanon A,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Bowden%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23315316" Bowden S,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Dore%20GJ%5BAuthor%5D&cauthor=true&cauthor_uid=23315316" Dore GJ,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Lewin%20SR%5BAuthor%5D&cauthor=true&cauthor_uid=23315316" Lewin SR, et al.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/23315316" Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. Clin Infect Dis 2013; 56:e87-94.
 HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Arendt%20E%5BAuthor%5D&cauthor=true&cauthor_uid=23131018" Arendt E,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Jaroszewicz%20J%5BAuthor%5D&cauthor=true&cauthor_uid=23131018" Jaroszewicz J,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Rockstroh%20J%5BAuthor%5D&cauthor=true&cauthor_uid=23131018" Rockstroh J,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Meyer-Olson%20D%5BAuthor%5D&cauthor=true&cauthor_uid=23131018" Meyer-Olson D,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Zacher%20BJ%5BAuthor%5D&cauthor=true&cauthor_uid=23131018" Zacher BJ,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Mederacke%20I%5BAuthor%5D&cauthor=true&cauthor_uid=23131018" Mederacke I, et al. Improved immune status corresponds with long-term decline of quantitative serum hepatitis B surface antigen in HBV/HIV co-infected patients.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/?term=arendt+e%2C+jaroszewicz" \o "Viral immunology." Viral Immunol 2012; 25:442-7.
Alvarez-Uria G, Ratcliffe L, Vilar J.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/19210695" Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort. HIV Med 2009; 10:269-73.
Coffin CS, Osiowy C, Myers RP, Gill MJ.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/23465393" Virology and clinical sequelae of long-term antiviral therapy in a North American cohort of hepatitis B virus (HBV)/human immunodeficiency virus type 1 (HIV-1) co-infected patients. J Clin Virol 2013; 57:103-8.
Heathcote EJ, Marcellin P, Buti M,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Gane%20E%5BAuthor%5D&cauthor=true&cauthor_uid=20955704" Gane E,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=De%20Man%20RA%5BAuthor%5D&cauthor=true&cauthor_uid=20955704" De Man RA,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Krastev%20Z%5BAuthor%5D&cauthor=true&cauthor_uid=20955704" Krastev Z, et al.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/20955704" Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140:132-43. 
 HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Gordon%20SC%5BAuthor%5D&cauthor=true&cauthor_uid=23364953" Gordon SC,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Krastev%20Z%5BAuthor%5D&cauthor=true&cauthor_uid=23364953" Krastev Z,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Horban%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23364953" Horban A,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Petersen%20J%5BAuthor%5D&cauthor=true&cauthor_uid=23364953" Petersen J,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Sperl%20J%5BAuthor%5D&cauthor=true&cauthor_uid=23364953" Sperl J,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Dinh%20P%5BAuthor%5D&cauthor=true&cauthor_uid=23364953" Dinh P, et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/?term=gordon+sc%2C+krastev+z" \o "Hepatology (Baltimore, Md.)." Hepatology 2013; 58:505-13. 
 HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Marcellin%20P%5BAuthor%5D&cauthor=true&cauthor_uid=23234725" Marcellin P,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Gane%20E%5BAuthor%5D&cauthor=true&cauthor_uid=23234725" Gane E,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Buti%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23234725" Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/23234725" \o "Lancet." Lancet 2013; 381:468-75. 
Sellier P, Schnepf N, Jarrin I,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Mazeron%20MC%5BAuthor%5D&cauthor=true&cauthor_uid=19897410" Mazeron MC,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Simoneau%20G%5BAuthor%5D&cauthor=true&cauthor_uid=19897410" Simoneau G,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Parrinello%20M%5BAuthor%5D&cauthor=true&cauthor_uid=19897410" Parrinello M, et al.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/19897410" Description of liver disease in a cohort of HIV/HBV coinfected patients. J Clin Virol 2010; 47:13-7. 
Mart�n-Carbonero L, Teixeira T, Poveda E,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Plaza%20Z%5BAuthor%5D&cauthor=true&cauthor_uid=21076274" Plaza Z,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Vispo%20E%5BAuthor%5D&cauthor=true&cauthor_uid=21076274" Vispo E,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Gonz%C3%A1lez-Lahoz%20J%5BAuthor%5D&cauthor=true&cauthor_uid=21076274" Gonz�lez-Lahoz J, et al.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/21076274" Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS 2011; 25:73-9. 
 HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Konopnicki%20D%5BAuthor%5D&cauthor=true&cauthor_uid=15802978" Konopnicki D,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Mocroft%20A%5BAuthor%5D&cauthor=true&cauthor_uid=15802978" Mocroft A,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=de%20Wit%20S%5BAuthor%5D&cauthor=true&cauthor_uid=15802978" de Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/15802978" \o "AIDS (London, England)." AIDS 2005; 19:593-601.
 HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Hoffmann%20CJ%5BAuthor%5D&cauthor=true&cauthor_uid=19550291" Hoffmann CJ,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Seaberg%20EC%5BAuthor%5D&cauthor=true&cauthor_uid=19550291" Seaberg EC,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Young%20S%5BAuthor%5D&cauthor=true&cauthor_uid=19550291" Young S,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Witt%20MD%5BAuthor%5D&cauthor=true&cauthor_uid=19550291" Witt MD,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=D'Acunto%20K%5BAuthor%5D&cauthor=true&cauthor_uid=19550291" D'Acunto K,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Phair%20J%5BAuthor%5D&cauthor=true&cauthor_uid=19550291" Phair J, et al. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/19550291" \o "AIDS (London, England)." AIDS 2009; 23:1881-9. 
Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, Moschidis Z, Sypsa V, Zavitsanos X, et al.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/19435436" Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis 2009; 48:1763-71.
Lincoln D, Petoumenos K, Dore GJ; Australian HIV Observational Database. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med 2003; 4:241�249.
De Luca A, Bugarini R, Lepri AC,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Puoti%20M%5BAuthor%5D&cauthor=true&cauthor_uid=12374521" Puoti M,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Girardi%20E%5BAuthor%5D&cauthor=true&cauthor_uid=12374521" Girardi E,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Antinori%20A%5BAuthor%5D&cauthor=true&cauthor_uid=12374521" Antinori A, et al, Italian Cohort Naive Antiretrovirals Study Goup. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 2002; 162:2125�2132.
 HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Matthews%20GV%5BAuthor%5D&cauthor=true&cauthor_uid=21716078" Matthews GV,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Manzini%20P%5BAuthor%5D&cauthor=true&cauthor_uid=21716078" Manzini P,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Hu%20Z%5BAuthor%5D&cauthor=true&cauthor_uid=21716078" Hu Z,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Khabo%20P%5BAuthor%5D&cauthor=true&cauthor_uid=21716078" Khabo P,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Maja%20P%5BAuthor%5D&cauthor=true&cauthor_uid=21716078" Maja P,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Matchaba%20G%5BAuthor%5D&cauthor=true&cauthor_uid=21716078" Matchaba G, et al. Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/?term=matthews+gv%2C+manzini+p" \o "AIDS (London, England)." AIDS 2011; 25:1727-35.
Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, et al.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/19202627" Changes in cancer mortality among HIV-infected patients: the Mortalit� 2005 Survey. Clin Infect Dis 2009; 48:633-9.
 HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=MacDonald%20DC%5BAuthor%5D&cauthor=true&cauthor_uid=18350596" MacDonald DC,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Nelson%20M%5BAuthor%5D&cauthor=true&cauthor_uid=18350596" Nelson M,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Bower%20M%5BAuthor%5D&cauthor=true&cauthor_uid=18350596" Bower M,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Powles%20T%5BAuthor%5D&cauthor=true&cauthor_uid=18350596" Powles T. Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/?term=macdonald+dc%2C+nelson+m" \o "World journal of gastroenterology : WJG." World J Gastroenterol 2008; 14:1657-63.
 HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Br%C3%A4u%20N%5BAuthor%5D&cauthor=true&cauthor_uid=17692986" Br�u N,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Fox%20RK%5BAuthor%5D&cauthor=true&cauthor_uid=17692986" Fox RK,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Xiao%20P%5BAuthor%5D&cauthor=true&cauthor_uid=17692986" Xiao P,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Marks%20K%5BAuthor%5D&cauthor=true&cauthor_uid=17692986" Marks K,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Naqvi%20Z%5BAuthor%5D&cauthor=true&cauthor_uid=17692986" Naqvi Z,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Taylor%20LE%5BAuthor%5D&cauthor=true&cauthor_uid=17692986" Taylor LE, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol 2007; 47:527-37. 
Puoti M, Bruno R, Soriano V, Donato F, Gaeta GB, Quinzan GP, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 2004; 18:2285-2293.
 HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Merchante%20N%5BAuthor%5D&cauthor=true&cauthor_uid=22955438" Merchante N,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Merino%20E%5BAuthor%5D&cauthor=true&cauthor_uid=22955438" Merino E,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=L%C3%B3pez-Aldeguer%20J%5BAuthor%5D&cauthor=true&cauthor_uid=22955438" L�pez-Aldeguer J,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Jover%20F%5BAuthor%5D&cauthor=true&cauthor_uid=22955438" Jover F,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Delgado-Fern%C3%A1ndez%20M%5BAuthor%5D&cauthor=true&cauthor_uid=22955438" Delgado-Fern�ndez M,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Galindo%20MJ%5BAuthor%5D&cauthor=true&cauthor_uid=22955438" Galindo MJ, et al. Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/?term=merchante+n%2C+merino+e" \o "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America." Clin Infect Dis 2013; 56:143-50.
Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/16391218" Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73.
 HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Lai%20CL%5BAuthor%5D&cauthor=true&cauthor_uid=22806323" Lai CL,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Yuen%20MF%5BAuthor%5D&cauthor=true&cauthor_uid=22806323" Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology 2013; 57:399-408. 
Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28:1067-1077.
Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53:348-356.
Papatheodoridis GV, Manolakopoulos S, Touloumi G,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Vourli%20G%5BAuthor%5D&cauthor=true&cauthor_uid=21270118" Vourli G,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Raptopoulou-Gigi%20M%5BAuthor%5D&cauthor=true&cauthor_uid=21270118" Raptopoulou-Gigi M,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Vafiadis-Zoumbouli%20I%5BAuthor%5D&cauthor=true&cauthor_uid=21270118" Vafiadis-Zoumbouli I, et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut 2011; 60:1109-1116.
Chang TT, Liaw YF, Wu SS,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Schiff%20E%5BAuthor%5D&cauthor=true&cauthor_uid=20683932" Schiff E,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Han%20KH%5BAuthor%5D&cauthor=true&cauthor_uid=20683932" Han KH,  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed?term=Lai%20CL%5BAuthor%5D&cauthor=true&cauthor_uid=20683932" Lai CL, et al. Long-term entecavir therapy results in the reversal of fi
$%&./7LYdwx�������v����d���O> h�T�hT,OJQJ^JmH	sH	)h�T�h25�OJQJ\�]�^JmH	sH	#h�7�5�OJQJ\�]�^JmH	sH	#h�sS5�OJQJ\�]�^JmH	sH	)h�sShT,5�OJQJ\�]�^JmH	sH	#h{L�5�OJQJ\�]�^JmH	sH	#h5�OJQJ\�]�^JmH	sH	#h�!�5�OJQJ\�]�^JmH	sH	 hFEhT,OJQJ^JmH	sH	h�9�OJQJ^JmH	sH	h�=[OJQJ^JmH	sH	x�D	g	�	�	�	�	�	�	

"
8
_
�
�
�
�
���������������������dhgd�>1
$dha$gd�>1
$dha$gd�>1$dh��7$8$H$a$gd�>1$dh��7$8$H$a$gd�>1���������		1	B	C	D	g	t	u	�	�	�	�	�	�	����Ͻ��ύ������uj]juRH>hjt!OJQJ^Jhc!�OJQJ^Jhc!�5�OJQJ^Jh�/h�/OJQJ^Jh�/5�OJQJ^Jh�7�5�OJQJ^Jh�T�h�T�OJQJ^Jh�T�h�%|OJQJ^J h�T�h�T�OJQJ^JmH	sH	#h�T�h�T�H*OJQJ^JmH	sH	#h�T�hT,H*OJQJ^JmH	sH	#h�T�h�%|H*OJQJ^JmH	sH	 h�T�hT,OJQJ^JmH	sH	h]OJQJ^JmH	sH	�	�	�	�	�	�	�	�	�	�	�	�	








"
7
8
^
_
�
�
�
�
�
����Ƽ������Ƌ����t�eZMZMZMZMhc!�0J6�OJQJ^Jhc!�6�OJQJ^Jhc!�0J6�OJQJ\�^Jh'Ihc!�OJQJ^Jhjt!OJQJ^Jh�\~OJQJ^Jh�"�h#�OJQJ^Jh�"�h�"�OJQJ^Jh�"�hQ�OJQJ^Jh�"�OJQJ^Jh�.�hc!�OJQJ^Jh�.�hc!�5�OJQJ^Jhc!�5�OJQJ^Jhc!�OJQJ^Jh�m�OJQJ^J�
�
�
�
,-��#%&�����˻������zfRA/#hhj�h�lOJQJ]�^JmH	sH	 h�l6�OJQJ]�^JmH	sH	&hhj�h�l6�OJQJ]�^JmH	sH	&hhj�h�5�OJQJ]�^JmH	sH	 h[5n5�OJQJ]�^JmH	sH	h�T�hc!�OJQJh{L�OJQJh�T�h�T�OJQJh�T�5�OJQJhc!�5�OJQJhD1'OJQJ^JaJmH	sH	hc!�OJQJ^Jh�n�0J6�OJQJ^Jhc!�6�OJQJ^Jhc!�0J6�OJQJ^J
hc!�0J0
vwx���������������w$��dh��7$8$H$`��a$gd�4
$dha$gd�@�$dh��7$8$H$a$gd�$dh��7$8$H$a$gd�B=$dh��7$8$H$a$gd�>O$dh��7$8$H$a$gd�A$dh��7$8$H$a$gd�
$dha$gd�>1dhgd�>1
&7IMNRT^z���������
����̿浨����saRa>&h�
	h<|�OJQJ\�]�^JmH	sH	h<|�OJQJ]�^JmH	sH	#h�
	h<|�OJQJ]�^JmH	sH	#hhj�h�BOJQJ]�^JmH	sH	h�k�OJQJ]�^JmH	sH	h�lOJQJ^Jh�k�OJQJ^JhA/h�k�OJQJ^Jh�iQOJQJ^Jhhj�hY?~OJQJ^Jhhj�h�
�OJQJ^Jhhj�hiK>OJQJ^Jhhj�h�BOJQJ^Jhhj�h�]pOJQJ^J


.
/
0
7
9
<
=
I
S
T
X
b
j
k
r
���ʽ����yoyo^J=3h�iQOJQJ^Jh�>Oh�iQOJQJ^J&h�
	h�iQOJQJ\�]�^JmH	sH	 h�iQOJQJ\�]�^JmH	sH	h{L�OJQJ^Jh�>Oh�>OOJQJ^Jh�>Oh�>OOJQJ]�^Jh{L�OJQJ]�^Jh�>OhT,OJQJ]�^Jh�>OhT,6�OJQJ]�^Jh�lh�k�OJQJ^J&h�
	h<|�OJQJ\�]�^JmH	sH	 h�lOJQJ\�]�^JmH	sH	 h<|�OJQJ\�]�^JmH	sH	r
z
{
�
<RX�������ptv������������Ż�����ŭ����}iU&h�>Oh(�6�OJQJ]�^JmH	sH	&h�>OhT,6�OJQJ]�^JmH	sH	h�>OhT,OJQJ]�^J!h�>OhTnB*OJQJ^Jph# !h�>Oh?^eB*OJQJ^Jph# h�>Oh?^eOJQJ]�^Jh�iQOJQJ^Jh�jh�>OOJQJ^Jh{L�OJQJ^Jh�>OOJQJ^Jh�>Oh�v�OJQJ^Jh�>OhYMOJQJ^J $*FST_gl�����������ɷ�큥oɥ�^M<!h�>Oh�`OB*OJQJ^Jph# !h�>Oh�qB*OJQJ^Jph# !h�>Oh3H�B*OJQJ^Jph# #h�>Oh�`OJQJ]�^JmH	sH	#h�>Ohhx5OJQJ]�^JmH	sH	#h�>Oh%�OJQJ]�^JmH	sH	#h�>Oh3H�OJQJ]�^JmH	sH	#h�>Oh6&ROJQJ]�^JmH	sH	#h�>Oh�@DOJQJ]�^JmH	sH	#h�>Oh��OJQJ]�^JmH	sH	#h�>OhT,OJQJ]�^JmH	sH	�����8Ev�����������ݻ���t�bPb>- h�>OhH-OJQJ^JmH	sH	#h�>OhH-OJQJ]�^JmH	sH	#h�>Oh��OJQJ]�^JmH	sH	#h�>Oh�N�OJQJ]�^JmH	sH	#h�>OhY?~OJQJ]�^JmH	sH	#h�>Ohh/�OJQJ]�^JmH	sH	#h�>Oh3H�OJQJ]�^JmH	sH	 h�>Oh�6�OJQJ^JmH	sH	!h�>Oh��B*OJQJ^Jph# !h�>Oh�`OB*OJQJ^Jph# !h�>Oh�qB*OJQJ^Jph# !h�>Oh�>OB*OJQJ^Jph# ��58<ITabtxy}����̺���̖�tc�ct��Q?#h�>Oh�6�OJQJ]�^JmH	sH	#h�>OhY?~OJQJ]�^JmH	sH	 h�>Oh�OJQJ^JmH	sH	 h�>Oh�EjOJQJ^JmH	sH	 h�>Oh�=7OJQJ^JmH	sH	#h�>Oh�=7OJQJ]�^JmH	sH	#h�>Oh�N�OJQJ]�^JmH	sH	#h�>OhH-OJQJ]�^JmH	sH	#h�>Oh�OJQJ]�^JmH	sH	 h�>OhH-OJQJ^JmH	sH	 h�>Oha4�OJQJ^JmH	sH	��������������6��ͼͼ�ު͙��͙vdRA h�>Oh`AiOJQJ^JmH	sH	#h�>Oh`Ai6�OJQJ^JmH	sH	#h�>Oh�6�OJQJ^JmH	sH	#h�>Oh��OJQJ]�^JmH	sH	 h�>Ohh/�OJQJ^JmH	sH	 h�>Oh�@DOJQJ^JmH	sH	#h�>Oh�@DOJQJ]�^JmH	sH	 h�>Oha4�OJQJ^JmH	sH	 h�>Oh�OJQJ^JmH	sH	 h�>Ohi�OJQJ^JmH	sH	 h�>Oh�6�OJQJ^JmH	sH	67^_~��������uvwx�������ɷ�ۓ��ۄuaL5,h�hT,5�6�OJQJ\�]�^JmH	sH	)h�K+hT,5�OJQJ\�]�^JmH	sH	&h�5�6�OJQJ\�]�^JmH	sH	h�OJQJ\�^JmH	sH	h�OJQJ\�^JmH	sH	#h�>OhY?~OJQJ\�^JmH	sH	#h�>Oh(�OJQJ\�^JmH	sH	#h�>Oh�OJQJ\�^JmH	sH	#h�>Oh�]&OJQJ\�^JmH	sH	#h�>Oh]ROJQJ\�^JmH	sH	#h�>Oh`AiOJQJ\�^JmH	sH	����DITUV������#$%*Nac��˼�˛˼�ˌ˛�}kˌkYG�}�YG#h�@�h�{�6�CJOJQJ^JaJ#h�@�h)26�CJOJQJ^JaJ#h�@�hy�6�CJOJQJ^JaJh�46�CJOJQJ^JaJh2r�6�CJOJQJ^JaJhoa6�CJOJQJ^JaJ#h�@�h�uH6�CJOJQJ^JaJh�uH6�CJOJQJ^JaJ#h�@�h��6�CJOJQJ^JaJ#h�@�h�K+6�CJOJQJ^JaJ h�Z�hT,CJOJQJ^JaJc������������
-./1:���������������u�k�aWaMWCMh�uHOJQJ^Jh�@�OJQJ^Jh2r�OJQJ^Jh�	`OJQJ^JhoaOJQJ^JhA/hH�OJQJ^JhA/h�XOJQJ^JhA/h�I�OJQJ^Jh�{�OJQJ^Jh�4OJQJ^JhA/hy�OJQJ^J#h�@�h�,@6�CJOJQJ^JaJh�46�CJOJQJ^JaJhoa6�CJOJQJ^JaJ#h�@�h)26�CJOJQJ^JaJ�������%(+8?\}�������=�����ε�����{�pep�[QDhA/h�	`OJQJ^Jh�	`OJQJ^Jh�*OJQJ^Jh&�OJQJ\�^JhQOOJQJ\�^JhNtOJQJ\�^Jh\BPOJQJ\�^Jh;�OJQJ\�^Jhs-�hs-�OJQJ\�^Jh��OJQJ]�^JhNtOJQJ]�^JhA/h�,@OJQJ]�^JhA/h>s-OJQJ]�^Jh�	`5�OJQJ\�^JhoaOJQJ\�^Jh�@�OJQJ\�^J=?BK`art����������Ʒ���xiWC2 h2r�OJQJ\�]�^JmH	sH	&h�
	h�
	OJQJ\�]�^JmH	sH	#h�
	h�
	OJQJ]�^JmH	sH	h�3�OJQJ]�^JmH	sH	h�4OJQJ]�^JmH	sH	#h�
	hZOJQJ]�^JmH	sH	hZOJQJ]�^JmH	sH	hNtOJQJ]�^JmH	sH	h\BPOJQJ]�^JmH	sH	h;�OJQJ]�^JmH	sH	h�4OJQJ^Jh\BPOJQJ^JhA/h�	`OJQJ^JhoaOJQJ^J#$%79�������uy������ʹ﹧�sg[gOgC7gh�xjCJOJQJ^Jh�*CJOJQJ^Jh�3�CJOJQJ^Jh�<�CJOJQJ^Jh�J?CJOJQJ^JhT,CJOJQJ^J&h� hT,OJQJ\�]�^JmH	sH	&hZhT,5�OJQJ\�^JmH	sH	#h�4h� OJQJ]�^JmH	sH	 h�XOJQJ\�]�^JmH	sH	 h�SOJQJ\�]�^JmH	sH	&h�
	h�
	OJQJ\�]�^JmH	sH	 h�3�OJQJ\�]�^JmH	sH	���!_%,,,*/>/R/N6O69������������$��dh��7$8$H$`��a$gd�1�
$dha$gd�1�dhgdo$��dh��7$8$H$`��a$gd�>1$��dh��7$8$H$`��a$gd�N$dh��7$8$H$a$gd�>1dhgd�>1$��dh��7$8$H$`��a$gd� 
����Hh���MV���� CGKLPS`j}����������������ܸܸܬܠܠܠܔܔ܈ܠ���|�p|�d�dh�jUCJOJQJ^Jh�&'CJOJQJ^Jh�<�CJOJQJ^Jh&�CJOJQJ^Jh�uHCJOJQJ^Jh�c8CJOJQJ^Jh�v�CJOJQJ^Jh)sCJOJQJ^Jh�4CJOJQJ^Jh�Z�CJOJQJ^JhT,CJOJQJ^Jh�J?CJOJQJ^JhoaCJOJQJ^J'�����HJYcefjl�������/ 0 Q i � � 
!!!�!�!�!���������������ܸ���ܸ����Ĉ�|k]kh�uHCJOJQJ^JaJ h�\~h�\~CJOJQJ^JaJh�\~CJOJQJ^Jh�(�CJOJQJ^Jh]�CJOJQJ^Jh�n�CJOJQJ^Jh&�CJOJQJ^JhCQ�CJOJQJ^Jh�uHCJOJQJ^Jh�*CJOJQJ^JhT,CJOJQJ^Jh�jUCJOJQJ^Jh�c8CJOJQJ^J!�!�!�!u"�"�"�"�"�"#�#�#%%%%!%+%,%��ϼ�ߢ��߈�xhUB/x$h}r�h}r�OJQJ^JaJmH	sH	$h}r�h�<�OJQJ^JaJmH	sH	$h}r�h�jUOJQJ^JaJmH	sH	h�jUOJQJ^JaJmH	sH	h}r�OJQJ^JaJmH	sH	h�<�OJQJ^JaJmH	sH	h�9lOJQJ^JhT,OJQJ^JhO	�OJQJ^JaJmH	sH	$hO	�hO	�OJQJ^JaJmH	sH	h�(OJQJ^JaJmH	sH	hT,OJQJ^JaJmH	sH	 h�\~hT,CJOJQJ^JaJ,%/%5%=%A%M%Z%]%_%j%k%l%u%v%�%�%�%�%�%�%�%�%�%"&$&R&_&j&k&q&������𽰣��������n]LnL!h�jh�)�B*OJQJ^Jph# !h�jh|D-B*OJQJ^Jph# !h�jh�r�B*OJQJ^Jph# h�jhy1�OJQJ^Jhy1�OJQJ^Jh�jhT,OJQJ^Jh�jh"�OJQJ^Jh�jh�f�OJQJ^J$h�)�hT,OJQJ^JaJmH	sH	h�9lOJQJ^JaJmH	sH	h}r�OJQJ^JaJmH	sH	hT,OJQJ^JaJmH	sH	q&�&�&�&�&�&�&�&�&�&�&�&�&''d'h's'{'�'�'�'�'�'�'�'�'����̾�̝̾̾̾�~�~�m_QmC_h�jOJQJ^JmH	sH	hbUqOJQJ^JmH	sH	hCHpOJQJ^JmH	sH	 h8xRh�jOJQJ^JmH	sH	h�jB*OJQJ^Jph# !h�jh�jB*OJQJ^Jph# !h�jh"�B*OJQJ^Jph# h]V6�B*OJQJ^Jph# h]VB*OJQJ^Jph# !h�jh�]sB*OJQJ^Jph# !h�jh�)�B*OJQJ^Jph# !h�jh�r�B*OJQJ^Jph# �'�'(((($(-(/(:(T([(d(f(�(�(�(�(�(�(�(�(�()�)�)�)�)�)�)�����Ӵ������ӦӦ䕄sbQsbsbsb!h�Nh�,�B*OJQJ^Jph#  h�Nh�,�OJQJ^JmH	sH	 h�NhbUqOJQJ^JmH	sH	 h�Nh�jOJQJ^JmH	sH	 h�Nh6OJQJ^JmH	sH	h!R�OJQJ^JmH	sH	h�,�OJQJ^JmH	sH	 h8xRhCHpOJQJ^JmH	sH	 h8xRh�jOJQJ^JmH	sH	hCHpOJQJ^JmH	sH	h�jOJQJ^JmH	sH	�)�)**5*K*T*U*�*�*�*�*�*�*++J+K+i+j+�+�+�+�+�+�+�+�+�+
,,,,���޼ޫޫ��ޫޫޫޞ����v�ivivi�V$h�5;5�OJQJ\�^JaJmH	sH	h�Nh7�OJQJ^Jh�Nh�)�OJQJ^Jh�Nh��6�OJQJ^Jh�Nh��OJQJ^Jh�Nh�%�OJQJ^J!h�Nh��B*OJQJ^Jph# !h�Nh�bB*OJQJ^Jph# !h�Nh�)�B*OJQJ^Jph# !h�Nh�r�B*OJQJ^Jph#  h�Nh�NOJQJ^JmH	sH	 ,,$,I,S,\,q,~,�,�,�,5-<-=-V-`-d-h-j-k-l-v-w-��ͽͽ��͙ͭ��vfV�vVvFh�*�OJQJ^JaJmH	sH	h�*OJQJ^JaJmH	sH	h�9lOJQJ^JaJmH	sH	$h�a
h�.OJQJ^JaJmH	sH	h�.OJQJ^JaJmH	sH	'h�5�hT,5�OJQJ^JaJmH	sH	h\�OJQJ^JaJmH	sH	hzz�OJQJ^JaJmH	sH	hT,OJQJ^JaJmH	sH	h�}�OJQJ^JaJmH	sH	$hT,5�OJQJ\�^JaJmH	sH	w-~-�-�-�-../.1.n.y.z.�.�.�.�.�.�.�.�.�.�.�.�.�.�.////(/)/*/>/��ϿϯϟϏ��o����o�_�_�_��Z	ho5�h�\~OJQJ^JaJmH	sH	h�}�OJQJ^JaJmH	sH	h#e�OJQJ^JaJmH	sH	h�WKOJQJ^JaJmH	sH	h�*�OJQJ^JaJmH	sH	h\�OJQJ^JaJmH	sH	h�(OJQJ^JaJmH	sH	hT,OJQJ^JaJmH	sH	h��OJQJ^JmH	sH	#h�*�h��5�OJQJ^JmH	sH	!>/R/^/_/`/a/q/t/u/�/�/�/�/�/�/�/�/�/�/�/���Ķ������x��j\J\9 h�J�h�J�OJQJ^JmH	sH	#h�
�h�-�5�OJQJ^JmH	sH	h�-�OJQJ^JmH	sH	h�;�OJQJ^JmH	sH	hs�OJQJ^JmH	sH	 h�J�hT,OJQJ^JmH	sH	hl	�OJQJ^JmH	sH	 hy�hT,OJQJ^JmH	sH	hWOJQJ^JmH	sH	ho6�OJQJ^JmH	sH	#h_=4ho6�OJQJ^JmH	sH	#h_=4h��6�OJQJ^JmH	sH	h_=4hT,>*�/0000 0D0F0X0\0f0z0~0�0�0�0�0���ӳ���u�dS�D5h�9lOJQJ\�^JmH	sH	h�-�OJQJ\�^JmH	sH	 h�`�h�J�OJQJ^JmH	sH	 h�`�h�`�OJQJ^JmH	sH	 h�`�hu"�OJQJ^JmH	sH	h�-�OJQJ^JmH	sH	h�9lOJQJ^JmH	sH	 h�`�h)OJQJ^JmH	sH	h�;�OJQJ^JmH	sH	#h�J�h�J�H*OJQJ^JmH	sH	 h�J�h�J�OJQJ^JmH	sH	h�(OJQJ^JmH	sH	h�h�OJQJ^JmH	sH	�0�0�0�011.1>1b1d1f1x1|1�1�1�1�1�1�1�1�12<2��Ͼ�������{i_������UD h�J�h,%�OJQJ^JmH	sH	h�OJQJ^Jh�6�OJQJ^J#h�`�h�6�OJQJ\�^JmH	sH	h�
�OJQJ^Jh�9lOJQJ^Jh�l�OJQJ^Jh�-�OJQJ^Jh�l�h�l�OJQJ^Jh�-�OJQJ^JmH	sH	 h�`�h�`�OJQJ^JmH	sH	#h�`�h�`�OJQJ\�^JmH	sH	h�-�OJQJ\�^JmH	sH	h�
�OJQJ\�^JmH	sH	<2b2�2�2�2�2�2�2�2�2�2�2�2�2�2"3#3'3/3338393;3A3k3l3n3o3����������ᛍ��qcq���Uh�
�OJQJ^JmH	sH	hs�OJQJ^JmH	sH	h,%�OJQJ^JmH	sH	hWOJQJ^JmH	sH	h�OJQJ^JmH	sH	h6�OJQJ^JmH	sH	h�*OJQJ^JmH	sH	h=	OOJQJ^JmH	sH	h�(OJQJ^JmH	sH	h�9lOJQJ^JmH	sH	 h�J�h,%�OJQJ^JmH	sH	h�;�OJQJ^JmH	sH	o3y3�3�3�3�3�3�3�3�3�3�34B4�4�4�4�4�4�4�4�4�4�4����Ⱥ�����yhyZyIyIyIyI h':h�-�OJQJ^JmH	sH	hCHOJQJ^JmH	sH	 h':h':OJQJ^JmH	sH	 h':hMlOJQJ^JmH	sH	h�*OJQJ^JmH	sH	 h':h�]�OJQJ^JmH	sH	 h':h=	OOJQJ^JmH	sH	h�=7OJQJ^JmH	sH	hWOJQJ^JmH	sH	h=	OOJQJ^JmH	sH	h�
�OJQJ^JmH	sH	h':OJQJ^JmH	sH	�4�4�4�4�4�4�4�4�4�4�4�4:5;5>5?5@5C5G5I5O5U5Z5\5]5_5c5d5g5h5t5~5�5�5�5�5�5�5�5�5��ͿͿͱͣ�ͣ�Ϳ͕��s���e�e�Ϳͱ�ͿͿͿhZ=wOJQJ^JmH	sH	 h�2Hh�2HOJQJ^JmH	sH	 h�2Hh�1�OJQJ^JmH	sH	h�2HOJQJ^JmH	sH	hCHOJQJ^JmH	sH	h�
�OJQJ^JmH	sH	h�1�OJQJ^JmH	sH	 h_Uh�1�OJQJ^JmH	sH	 h':h�1�OJQJ^JmH	sH	 h':hWOJQJ^JmH	sH	'�5�5�5�56)696@6N6O6f6g6h6i6m6�6�6�6�6�6	7
77�78808m8��������ű��}�}l[l[�Ml}�}�}h�*OJQJ^JmH	sH	 h{7�h{7�OJQJ^JmH	sH	 h{7�h�]�OJQJ^JmH	sH	 h>i�h�]�OJQJ^JmH	sH	 ho6�OJQJ]�^JmH	sH	#h_=4hoOJQJ]�^JmH	sH	&h_=4h�]�6�OJQJ]�^JmH	sH	h2i�OJQJ^JmH	sH	h�9lOJQJ^JmH	sH	h�1�OJQJ^JmH	sH	 h_Uh�1�OJQJ^JmH	sH	m8t8�8�8999999%9&9,91969@9D9Z9\9]9o9s9��п���ᱜ�yky]O]y]OAh�9lOJQJ^JmH	sH	h�*OJQJ^JmH	sH	h� qOJQJ^JmH	sH	h�a�OJQJ^JmH	sH	 h>i�h�khOJQJ^JmH	sH	#h_=4h�kh>*OJQJ^JmH	sH	)h_=4h�kh6�>*OJQJ]�^JmH	sH	h_=4OJQJ^JmH	sH	 hCHhoOJQJ^JmH	sH	 hCHh�]�OJQJ^JmH	sH	 h>i�h�]�OJQJ^JmH	sH	h�zOJQJ^JmH	sH	9&9e:u:�;�;�=:?D?V?B���������o$��dh��7$8$H$`��a$gdj�dh��7$8$H$gd;E$��dh��7$8$H$`��a$gd;Edh��7$8$H$gd�>1$��dh��7$8$H$`��a$gd�>1$
��dh��7$8$H$a$gd�>1$��dh��7$8$H$`��a$gd�>=
$dha$gd_=4
s9y9�9�9�9�9�9�9�9�9:::=:b:c:e:u:}:~:�:�:����Ŵ�����򣴣ӀrdSB hCHhD:�OJQJ^JmH	sH	 hCHh�b�OJQJ^JmH	sH	h�b�OJQJ^JmH	sH	hD:�OJQJ^JmH	sH	)h_=4hT,6�>*OJQJ]�^JmH	sH	h�*OJQJ^JmH	sH	 hCHh�khOJQJ^JmH	sH	 hCHh�$WOJQJ^JmH	sH	h�$WOJQJ^JmH	sH	 h>i�h�khOJQJ^JmH	sH	h�$OJQJ^JmH	sH	h2i�OJQJ^JmH	sH	�:�:�:�:�:�:�:�:�:�:�:�:�:�:�:�:G;N;P;X;Y;];b;e;f;g;u;����N���s���e�eWesWsWEWs#h�1�h)-H*OJQJ^JmH	sH	h)-OJQJ^JmH	sH	h�xOJQJ^JmH	sH	h�1�OJQJ^JmH	sH	 h8xRhT,OJQJ^JmH	sH	h�b�OJQJ^JmH	sH	h�/=OJQJ^JmH	sH	h2i�OJQJ^JmH	sH	 hCHh�/=OJQJ^JmH	sH	 hCHh�b�OJQJ^JmH	sH	 hCHh�`OJQJ^JmH	sH	 hCHhT,OJQJ^JmH	sH	u;x;�;�;�;�;�;�;�;�;�;�;�;�;�;�;�;�;���Ⱥ�����Ȃt`L;-h'`�OJQJ^JmH	sH	 h*N}h'`�OJQJ^JmH	sH	&hc�hT,5�OJQJ\�^JmH	sH	&h�(�5�6�OJQJ\�]�^JmH	sH	hT,OJQJ^JmH	sH	h�jOJQJ^JmH	sH	h�W�OJQJ^JmH	sH	h�@OJQJ^JmH	sH	h3�OJQJ^JmH	sH	h�ZOJQJ^JmH	sH	h�$'OJQJ^JmH	sH	h)-OJQJ^JmH	sH	h�/=OJQJ^JmH	sH	h�xOJQJ^JmH	sH	�;<C<E<M<]<_<�<�<�<�<�<�<�<===%=,=.=�=�=�=�=�=�=�����ᷦ��������v��e�eTC� hCHha|�OJQJ^JmH	sH	 hCHhbUqOJQJ^JmH	sH	 hCHh�7�OJQJ^JmH	sH	h�9lOJQJ^JmH	sH	 hCHh*N}OJQJ^JmH	sH	 hCHh�nOJQJ^JmH	sH	 hCHhT,OJQJ^JmH	sH	h�7�OJQJ^JmH	sH	h��OJQJ^JmH	sH	h�.�OJQJ^JmH	sH	h'`�OJQJ^JmH	sH	 h�ph'`�OJQJ^JmH	sH	�=�=�=*>@>F>w>�>�>�>�>�>?
?)?3?9?:?;?C?D?���ŷ��өӛ���n\G5#hT,5�6�OJQJ]�^JmH	sH	)hbUqhT,5�6�OJQJ]�^JmH	sH	#h;E5�6�OJQJ]�^JmH	sH	 h;EhT,OJQJ^JmH	sH	h�-OJQJ^JmH	sH	h��OJQJ^JmH	sH	h'`�OJQJ^JmH	sH	h�xOJQJ^JmH	sH	h�9lOJQJ^JmH	sH	h�zOJQJ^JmH	sH	h
QOJQJ^JmH	sH	hPenOJQJ^JmH	sH	 h*N}hT,OJQJ^JmH	sH	D?V?d?j??�?�?�?�?�?�?�?�?�?�?�?�?�?����ͼ������{gSB1 h�`Oh�h�OJQJ^JmH	sH	 h�`Oh8l�OJQJ^JmH	sH	&h�`Oh�-�5�OJQJ\�^JmH	sH	&h�`Oh8l�5�OJQJ\�^JmH	sH	 h�`OhT,OJQJ^JmH	sH	h�y_B*OJQJ^Jph# !h�`Oh8l�B*OJQJ^Jph# !h�`Oh��B*OJQJ^Jph#  h��h��OJQJ^JmH	sH	h�pAOJQJ^JmH	sH	 h��hT,OJQJ^JmH	sH	&h;Eh;E6�OJQJ]�^JmH	sH	�?�?�?@@=@R@]@r@s@�@�@�@�@A#A0AXAxA�A�A��п������{�m�_Q_C_�h+jtOJQJ^JmH	sH	hehOJQJ^JmH	sH	hj�OJQJ^JmH	sH	h�2OJQJ^JmH	sH	&h��hT,5�OJQJ\�^JmH	sH	 h��hT,OJQJ^JmH	sH	 h��h8l�OJQJ^JmH	sH	h�h�OJQJ^JmH	sH	 h�`Oh�h�OJQJ^JmH	sH	 h�`Oh8l�OJQJ^JmH	sH	 h�`Oh0�OJQJ^JmH	sH	h�xOJQJ^JmH	sH	�A�A�A�A�A�A�ABB&B5BCBDBLBMBNBVBWBXBYB\B������ӱ����ve�SD5Seh@B5�OJQJ^JmH	sH	hjt!5�OJQJ^JmH	sH	#h�e�h�b)5�OJQJ^JmH	sH	 h|Dh�b)OJQJ^JmH	sH	h�y_OJQJ^JmH	sH	h�b)OJQJ^JmH	sH	 h|DhT,OJQJ^JmH	sH	h�=MOJQJ^JmH	sH	 hj�h
OJQJ^JmH	sH	 h*N}h
OJQJ^JmH	sH	h
OJQJ^JmH	sH	h�2OJQJ^JmH	sH	 h��h�}OJQJ^JmH	sH	\B�B�B�B�BCCCC0ChCmC�C�C�C�C�C�C�C�C�C�CDDADBDCDDDcDdDeD�����������дЦИ��‡‡�p���^�#h|DhT,H*OJQJ^JmH	sH	,h�rqhT,5�B*OJQJ^JmH	phsH	 h|Dh�n�OJQJ^JmH	sH	h�F?OJQJ^JmH	sH	h�xOJQJ^JmH	sH	hU4OJQJ^JmH	sH	h�n�OJQJ^JmH	sH	 h|DhT,OJQJ^JmH	sH	hVe�OJQJ^JmH	sH	 h|DhVe�OJQJ^JmH	sH	eD�D�D�D�D�D�D�D�D�D�D�D�D�D�DEEE6E[E�E�E��Ͻ����{jYHjHj{�{�j{ hVe�h�2�OJQJ^JmH	sH	 hVe�h�2OJQJ^JmH	sH	 hVe�hd�OJQJ^JmH	sH	 hVe�hT,OJQJ^JmH	sH	 hVe�h"Q,OJQJ^JmH	sH	 hVe�h|DOJQJ^JmH	sH	h@B5�OJQJ^JmH	sH	#h�n�h�n�5�OJQJ^JmH	sH	#h�n�hU45�OJQJ^JmH	sH	h�n�OJQJ^JmH	sH	 h|Dho�OJQJ^JmH	sH	B�E�E�I�I�NSSmV�Z�\���������p$��dh��7$8$H$`��a$gd��$dh��7$8$H$a$gd��$��dh��7$8$H$`��a$gd�vw
$dha$gd�q$dh��7$8$H$a$gd�
@$��dh��7$8$H$`��a$gd�-dh��7$8$H$gd�>1$��dh��7$8$H$`��a$gd"Q,
�E�E�E�E�E�E�E�E�E�E�E�E�E�E�E�E�EFF%FMFNFXF��ʹ��������yhZhZhZI;Ih�y_B*OJQJ^Jph# !h�`Ohe�B*OJQJ^Jph# h�y_OJQJ^JmH	sH	 h��h�y_OJQJ^JmH	sH	 h�`Oh�y_OJQJ^JmH	sH	#h�h�he�5�OJQJ^JmH	sH	he�5�OJQJ^JmH	sH	he�OJQJ^JmH	sH	 h�h�he�OJQJ^JmH	sH	 hT,6�OJQJ]�^JmH	sH	&h�h�hT,6�OJQJ]�^JmH	sH	 h1h|hT,OJQJ^JmH	sH	XF^FfF�F�F�F�F�FGGHGMGhG~G�G�G�G�GHHH.HjH����ҳ�ėĥ�y�j�[L=L[�hF!LOJQJ]�^JmH	sH	h�,sOJQJ]�^JmH	sH	hu�OJQJ]�^JmH	sH	h�b)OJQJ]�^JmH	sH	hVe�OJQJ]�^JmH	sH	h�-OJQJ]�^JmH	sH	h�b)B*OJQJ^Jph# hVe�OJQJ^JmH	sH	 h�h�h�-OJQJ^JmH	sH	he�B*OJQJ^Jph# h�-B*OJQJ^Jph# !h�`Ohe�B*OJQJ^Jph# h�y_B*OJQJ^Jph# jHvHzH~H�H�HdIqII�I�I�I�I�I�I�I�I�I�I�IJ#J+JdJ������ô�᠏�qbqSqbqDqbh"	ROJQJ\�^JmH	sH	h�xuOJQJ\�^JmH	sH	h�8OJQJ\�^JmH	sH	hq�OJQJ\�^JmH	sH	h�n#OJQJ\�^JmH	sH	 hT,5�OJQJ\�^JmH	sH	&h�*FhT,5�OJQJ\�^JmH	sH	hF!LOJQJ]�^JmH	sH	h�xuOJQJ]�^JmH	sH	hVe�OJQJ]�^JmH	sH	h�-OJQJ]�^JmH	sH	h\%�OJQJ]�^JmH	sH	dJlJ�J�J�J�J�J�J�J(K)K@KOKRK]KdKpKtKyK}K~K�K�K�K���ôå�����xiZiKiZK<ixh�B�OJQJ\�^JmH	sH	h�b)OJQJ\�^JmH	sH	h��OJQJ\�^JmH	sH	hP�OJQJ\�^JmH	sH	hfOJQJ\�^JmH	sH	h3a<OJQJ\�^JmH	sH	h�k�OJQJ\�^JmH	sH	h��OJQJ\�^JmH	sH	h�@OJQJ\�^JmH	sH	h)8�OJQJ\�^JmH	sH	h�8OJQJ\�^JmH	sH	hq�OJQJ\�^JmH	sH	h�_OJQJ\�^JmH	sH	�K�K�K�K�K�K�K�K�K�KLLL1LCLQL\LqLxL}L�L�L�L�L�L�L������𴥴��x�x�i�Z�i�iK�h-5OJQJ\�^JmH	sH	hVe�OJQJ\�^JmH	sH	hxZ[OJQJ\�^JmH	sH	h��OJQJ\�^JmH	sH	h�
�OJQJ\�^JmH	sH	h�
@OJQJ\�^JmH	sH	h�B�OJQJ\�^JmH	sH	h��OJQJ\�^JmH	sH	h�b)OJQJ\�^JmH	sH	hfOJQJ\�^JmH	sH	h��OJQJ\�^JmH	sH	hP�OJQJ\�^JmH	sH	�LMM&M'M*M+M,M;M=MAMEM[M�M�M�M�M�M�M�M�M�MNNN%N*N+NNN�����������x��i�i��Z�Z�Kh�_OJQJ\�^JmH	sH	h�
@OJQJ\�^JmH	sH	h*i�OJQJ\�^JmH	sH	h��OJQJ\�^JmH	sH	hS�OJQJ\�^JmH	sH	hxZ[OJQJ\�^JmH	sH	hVe�OJQJ\�^JmH	sH	h�xuOJQJ\�^JmH	sH	h�
�OJQJ\�^JmH	sH	h��OJQJ\�^JmH	sH	h��OJQJ\�^JmH	sH	h�7AOJQJ\�^JmH	sH	NNbNcN~N�N�N�N�N�N�N�NOOCOGOTOUO`OaO�����x�i�i�WH6#h�8hF�OJQJ\�^JmH	sH	hoaOJQJ\�^JmH	sH	#h�8h6g�OJQJ\�^JmH	sH	h�l<OJQJ\�^JmH	sH	h��OJQJ\�^JmH	sH	haOJQJ\�^JmH	sH	h�*FOJQJ\�^JmH	sH	h�
@OJQJ\�^JmH	sH	hfDAOJQJ\�^JmH	sH	h�7AOJQJ\�^JmH	sH	h�"�OJQJ\�^JmH	sH	h�_OJQJ\�^JmH	sH	h�b)OJQJ\�^JmH	sH	aObOcOdO�O�O�O�O�O�O�O�OP
PPPP P!P#P��̺��̙��̺��udSB� h�"�hTiDOJQJ^JmH	sH	 h�"�hoaOJQJ^JmH	sH	 h�"�hgn�OJQJ^JmH	sH	#h�"�h�xOJQJ\�^JmH	sH	#h�"�h*h�OJQJ\�^JmH	sH	#h�"�hAI)OJQJ\�^JmH	sH	hyG�OJQJ\�^JmH	sH	#h�"�h�FOJQJ\�^JmH	sH	#h�"�h�FeOJQJ\�^JmH	sH	#h�8hF�OJQJ\�^JmH	sH	h��OJQJ\�^JmH	sH	#P1P5P6PSPTPVP_P�P�P�P�P�P QKQ�Q�Q�Q�Q�Q��ͼͫ����xgxYKYKY=h�c�OJQJ^JmH	sH	hyG�OJQJ^JmH	sH	hG{OJQJ^JmH	sH	 h�"�ht3�OJQJ^JmH	sH	 h�"�hG{OJQJ^JmH	sH	 h�"�h�c�OJQJ^JmH	sH	 h�"�huaOJQJ^JmH	sH	 h�"�hyv�OJQJ^JmH	sH	 h�"�h�P�OJQJ^JmH	sH	 h�"�h*h�OJQJ^JmH	sH	 h�"�h�{%OJQJ^JmH	sH	 h�"�h")?OJQJ^JmH	sH	�Q�Q�Q�Q�QRRRRR"R&R,R0R7R�R�R�R�R�R�R�R�R�R�R�R�R����Ⱥ�䛍��֍��qq`qRDRh
gVOJQJ^JmH	sH	h�'OJQJ^JmH	sH	 hc7�hT,OJQJ^JmH	sH	h�l<OJQJ^JmH	sH	h;OJQJ^JmH	sH	h�*�OJQJ^JmH	sH	h|QVOJQJ^JmH	sH	 hc7�hs@OJQJ^JmH	sH	h�qOJQJ^JmH	sH	hI�OJQJ^JmH	sH	h��OJQJ^JmH	sH	hyG�OJQJ^JmH	sH	h�xOJQJ^JmH	sH	�R
SSSSSSSSSYShS�S�S�S�S���Ⱦ����zo]N?4h��OJQJ\�^Jh]z�OJQJ]�^JmH	sH	h�A�OJQJ]�^JmH	sH	#h?#�h�A�OJQJ]�^JmH	sH	h�A�OJQJ\�^Jh�"�h�A�OJQJ\�^Jh�"�OJQJ\�^J h�I�h[`�OJQJ^JmH	sH	hS'
h�vwOJQJ^JhS'
h47OJQJ^JhS'
OJQJ^JhoaOJQJ^JmH	sH	hi'�OJQJ^JmH	sH	h�'OJQJ^JmH	sH	h�l<OJQJ^JmH	sH	�S�S�S�S�S�S�STT)T+TDTJT�T�T�TU!U/U>UeUoU�U�U�U�U�U�U�U�U�U�U�U�U�UVVV%V������ۺ��������������������xm�mh��OJQJ\�^Jh��OJQJ\�^Jh3�OJQJ\�^JhZ;�OJQJ\�^Jh"wOJQJ\�^Jh�vwOJQJ\�^Jh�b)OJQJ\�^Jh�o�OJQJ\�^Jh!-�OJQJ\�^Jh�A�OJQJ\�^Jh��OJQJ\�^Jh?#�h��OJQJ\�^Jh%OJQJ\�^J&%V(VkVlVmVnVoVqVrV�V�V�V�V�V�V�V�V�V�V�V�V�V�V����Ƚ������u��j_�T��B#h�s�h�s�OJQJ]�^JmH	sH	h"wOJQJ\�^Jh��OJQJ\�^Jh�0�OJQJ\�^Jh�W�OJQJ\�^JhjB�OJQJ\�^Jh�UOJQJ\�^Jh�"�h��OJQJ\�^Jh�s�h��OJQJ\�^Jh	sOJQJ\�^Jh�\,OJQJ\�^Jh�gXOJQJ\�^Jh�0OJQJ\�^Jh;0�OJQJ\�^Jh��OJQJ\�^Jhh�OJQJ\�^J�V�V�VW>WDW�W�W�W�W�W�W�W�W�W�WX X!X*X=X?XDXGXnX�X�X�X�X������ϵ�����偌v�kvk`kUv�UJh3p�OJQJ\�^Jh$IOJQJ\�^Jh"wOJQJ\�^Jh�s�OJQJ\�^Jh�UOJQJ\�^Jh�0OJQJ\�^JhS.�OJQJ\�^JhG�OJQJ]�^JmH	sH	h�b�OJQJ]�^JmH	sH	h�0�OJQJ]�^JmH	sH	h;OJQJ\�^Jh�0�OJQJ\�^Jh�\,OJQJ\�^Jh��OJQJ\�^Jh;OJQJ]�^JmH	sH	�X�X�X�X�X�X�X�X�X�X�X�X�X�XY	YYY Y)Y*Y,Y6YFYJYNYYYbYkYpYsY|Y�Y�Y�Y�Y�Y�Y����������Ƚ����Ƚ�Ȳ����Ƚ��Ƚ�Ȝx�f#h�s�h]K�OJQJ]�^JmH	sH	h�%:OJQJ\�^JhvG�OJQJ\�^Jh�s�h�gXOJQJ\�^Jh�}�OJQJ\�^Jh�tSOJQJ\�^Jh��OJQJ\�^Jh3p�OJQJ\�^JhG�OJQJ\�^Jh"wOJQJ\�^Jh[~pOJQJ\�^Jh�0OJQJ\�^Jh$IOJQJ\�^J%�Y�Y�Y�Y�Y	ZZZZ/ZGZOZQZxZ|Z�Z�Z�Z�Z�Z[[[[[ [+[-[5[���������ޢ��uބ�f�WfHWHfWh�fOJQJ]�^JmH	sH	h�1�OJQJ]�^JmH	sH	hLkOJQJ]�^JmH	sH	h��OJQJ]�^JmH	sH	hVH�OJQJ]�^JmH	sH	h�o�OJQJ]�^JmH	sH	hDt�OJQJ]�^JmH	sH	h�xOJQJ]�^JmH	sH	h�S=OJQJ]�^JmH	sH	hD7NOJQJ]�^JmH	sH	h�u�OJQJ]�^JmH	sH	#h�s�h�9OJQJ]�^JmH	sH	5[:[>[C[G[V[l[�[�[�[�[�[�[\\:\C\D\p\r\}\�\�\�\�\�\�\�\�\�\�\�\]=]N]���������Ҵ�å��å���������u�u�fWfh6-OJQJ]�^JmH	sH	h�'POJQJ]�^JmH	sH	#h,h>�OJQJ]�^JmH	sH	hVH�OJQJ]�^JmH	sH	h�fOJQJ]�^JmH	sH	h>�OJQJ]�^JmH	sH	h&7OJQJ]�^JmH	sH	h�%:OJQJ]�^JmH	sH	h�zOJQJ]�^JmH	sH	h�1�OJQJ]�^JmH	sH	hLkOJQJ]�^JmH	sH	"N]P]�]�]�]�]�]	^
^^^^^'^-^<^Y^Z^]^^^s^t^v^�^�^�^�^�^�^�^���������å���Öx�x�x�ixix�W#h�"�h"v�OJQJ]�^JmH	sH	h*s�OJQJ]�^JmH	sH	h"v�OJQJ]�^JmH	sH	h�UOJQJ]�^JmH	sH	h�s�OJQJ]�^JmH	sH	hDt�OJQJ]�^JmH	sH	h3s!OJQJ]�^JmH	sH	h6-OJQJ]�^JmH	sH	hCeXOJQJ]�^JmH	sH	h�'POJQJ]�^JmH	sH	hjhOJQJ]�^JmH	sH	�^�^�^�^	_____ _,_-_7_D_J_P_W_X_`_i_k_��ɷ����u�fufWfuH9HfhfR�OJQJ]�^JmH	sH	h28OJQJ]�^JmH	sH	h�+OJQJ]�^JmH	sH	h,OJQJ]�^JmH	sH	h�1�OJQJ]�^JmH	sH	h�sOJQJ]�^JmH	sH	#h�"�h�sOJQJ]�^JmH	sH	#h�"�h;0�OJQJ]�^JmH	sH	#h�"�h�9OJQJ]�^JmH	sH	#h�"�h,OJQJ]�^JmH	sH	#h�"�h"v�OJQJ]�^JmH	sH	#h�"�h5J�OJQJ]�^JmH	sH	k_m_n_|_�_�_�_�_�_�_�_�_�_�_�_````+`1`D`R`S`���ô����x�x�҇�iZK�<�<hl9�OJQJ]�^JmH	sH	h�%�OJQJ]�^JmH	sH	h�,sOJQJ]�^JmH	sH	h�sOJQJ]�^JmH	sH	hfR�OJQJ]�^JmH	sH	h�N@OJQJ]�^JmH	sH	h5J�OJQJ]�^JmH	sH	h�"�OJQJ]�^JmH	sH	h�+OJQJ]�^JmH	sH	h�UOJQJ]�^JmH	sH	h28OJQJ]�^JmH	sH	h,OJQJ]�^JmH	sH	h3s!OJQJ]�^JmH	sH	S`T`Y`Z`\`]`f`g`o`�`�`�`�`a7a9a;a<aza�abjbnbtb{b����ô���������x�i�\O\Bh��OJQJ\�]�^Jh�-�OJQJ\�]�^Jh�5OJQJ\�]�^Jh�1�OJQJ]�^JmH	sH	h"iOJQJ]�^JmH	sH	h�xGOJQJ]�^JmH	sH	h?�OJQJ]�^JmH	sH	h�
:OJQJ]�^JmH	sH	h=M�OJQJ]�^JmH	sH	h�fOJQJ]�^JmH	sH	h5J�OJQJ]�^JmH	sH	h3s!OJQJ]�^JmH	sH	h�sOJQJ]�^JmH	sH	�\]`�elg�i�i�i�i�i�i�i�i�i�i�i�i�i�i�i�i�������������������$dh��7$8$H$a$gd�R�$��dh��7$8$H$`��a$gd�$��dh��7$8$H$`��a$gd�E$��dh��7$8$H$`��a$gdHD�{b�b�b�b�b�b�bccjctc{c�c�c�c�c�c�c�c�c�c�c�c������楘�̥�~o]oKo>h��OJQJ\�]�^J#hq {hq {OJQJ]�^JmH	sH	#hq {h�MOJQJ]�^JmH	sH	hq {OJQJ]�^JmH	sH	h=M�OJQJ\�]�^Jh�5OJQJ\�]�^JhsW�OJQJ\�]�^Jh��OJQJ\�]�^Jh�D�OJQJ\�]�^Jh�fOJQJ\�]�^Jh3s!OJQJ\�]�^Jh�N@OJQJ\�]�^Jh�-�OJQJ\�]�^JhoCOJQJ\�]�^J�c�c�cdd d!d$d-d.d0d9dDdSdTdfdjdtd�d�d�d�d�d�d�d�d�d�d!e�������ּ֯����������u�h�X�hq {h�5OJQJ\�]�^JhaROJQJ\�]�^Jh�UOJQJ\�]�^Jhq {h�#�OJQJ\�]�^Jh�#�OJQJ\�]�^Jhq {h�5�OJQJ\�]�^Jh=M�OJQJ\�]�^Jh�1�OJQJ\�]�^Jh��OJQJ\�]�^Jh�"�OJQJ\�]�^Jhq {h(=OJQJ\�]�^Jhq {OJQJ\�]�^J!e"e+e@eIeqese�e�e�e�e�e�e�e�e�e�e�e�e�e�e
fff!f,f@f���������Ӧ�㦖�zi�[M[ih�n�OJQJ^JmH	sH	h`sOJQJ^JmH	sH	 h�RhT,OJQJ^JmH	sH	h�EOJQJ^JmH	sH	h�1�OJQJ^JmH	sH	hq {h(=OJQJ\�]�^Jhq {h�#�OJQJ\�]�^JhfR�OJQJ\�]�^Jhq {hs	�OJQJ\�]�^Jhq {h��OJQJ\�]�^Jh�#�OJQJ\�]�^Jhq {h+s�OJQJ\�]�^J@fAfBfWfnf}ff�f�f�f�f�f�f�f�f�fg&g/g5g6glgyg�g�g�g�g0h;hsh�h�h����Ӵ���ӣӣ�ӣ�ţ����ufufufuXh�O�B*OJQJ^Jph# h�OJQJ\�^JmH	sH	#h�R�h�OJQJ\�^JmH	sH	h�OJQJ^JmH	sH	h�"�OJQJ^JmH	sH	 h�Rh�ROJQJ^JmH	sH	 h�RhT,OJQJ^JmH	sH	h?COJQJ^JmH	sH	h`sOJQJ^JmH	sH	 h�Rh%E?OJQJ^JmH	sH	h+s�OJQJ^JmH	sH	�h�h�h�hicikiri�i�i�i�i�i�i�i�i�i1j2j����ôåô��p^O>1>h�P(h�P(OJQJ^J!jh�P(h�P(OJQJU^Jh�P(h�tuOJPJQJ^J#h�R�h�G�OJQJ\�^JmH	sH	#h�G�h�G�5�OJQJ^JmH	sH	h�"�5�OJQJ^JmH	sH	&h�E5�6�OJQJ\�]�^JmH	sH	h�[�OJQJ\�^JmH	sH	h�O�OJQJ\�^JmH	sH	h�OJQJ\�^JmH	sH	h�[�B*OJQJ^Jph# h�O�B*OJQJ^Jph# !h�O�h�O�B*OJQJ^Jph# 2j9j:j<j=j�j�j�j�j�j�j.k/k6k7k9k>k?k@kCk�k�k�k�k�k�k�k�k�klql�����������������ɺ�����{k�\M\h�"ih/�OJPJQJ^Jh�"ih�D�OJPJQJ^Jh�"ih�#�5�OJPJQJ^Jh�"ih�#�OJPJQJ^J"h�"ih�tu6�OJPJQJ]�^Jh�"ih�LbOJPJQJ^Jh�"ih�tuOJPJQJ^Jhi=h�tuOJPJQJ^Jh�P(h�tuOJPJQJ^Jh/�OJQJ^J!jh�P(h�P(OJQJU^Jh�P(h�P(OJQJ^J�i�k�l�monuru�v�w*z{)|[}�~���������������2$
&F-DM�
����a$gd�-� $
&Fa$gd�-�!$
&Fa$gd�-�!$
&Fa$gd�\j!$
&Fa$gdtE�!$
&Fa$gd!AP $
&Fa$gdi=
&F-DM�
����gdi=$
&F7$8$H$a$gdi=ql{l�l�l�l�l�l�l�l�l�l�l�l�l�lmm�m�m�m���߱������oYoYDYo(h�"ihi=0J>*B*OJQJ^Jph*jh�"ihi=B*OJQJU^Jph!h�"ihi=B*OJQJ^Jphh�"ih�"iOJQJ^J!h�"ihD�B*OJQJ^Jph$h�"ihD�B*OJQJ\�^Jphh�"ihi=OJPJQJ^Jh�"ih/�5�OJPJQJ^Jh�"ih/�OJPJQJ^Jh�"ih�D�OJPJQJ^J"h�"ih�D�6�OJPJQJ]�^J�m�m�m�m�m�m�m�m�m�m�mKnZn[n_n`n��Ⱥ�ۛ��yhTA0h h�"iha�OJQJ^JmH	sH	$hi=ha�0JOJQJ^JmH	sH	'h�"iha�0J6�OJQJ^JmH	sH	 hi=ha�OJQJ^JmH	sH	hi=hi=OJPJQJ^J$h�"ihD�5�B*OJQJ^Jphh�"iB*OJQJ^Jph!h�"ihD�B*OJQJ^JphhmR�B*OJQJ^Jph$h�"ihD�6�B*OJQJ^Jph!hi=hD�B*OJQJ^Jph%h�"ihD�0J#B*OJQJ^Jph`nancnnnonpn�n�n�n�n�n�nlomo{o|o~oo�o�o�o�o�o�olpmpsptpvpwp�p�pqqqqvqwq�q�q�q�qr��;��������������������������������������%hi=hi=0JB*OJQJ^Jph!hi=hi=B*OJQJ^Jph*jhi=hi=B*OJQJU^Jphhi=ha�OJPJQJ^J hi=ha�OJQJ^JmH	sH	'h�"iha�0J5�OJQJ^JmH	sH	h�"iOJQJ^JmH	sH	*rr\r]rarbrcrdrhrirjrlr~r�r�r�r�rssssss�s�s�s�s�����Ŵ�����o�bQDQDQDQDQDQh�"ih�"iOJQJ^J!jh�"ih�"iOJQJU^Jh�"ihi=OJQJ^J$hi=hi=B*OJQJ\�^Jph$h�"ih�"i5�B*OJQJ^Jphh�"iB*OJQJ^Jph!h�"ihi=B*OJQJ^Jph!hi=hi=B*OJQJ^JphhmR�6�B*OJQJ^Jph$h�"ihi=6�B*OJQJ^Jph-jh�"ihi=6�B*OJQJU^Jph�s�s�stt!t"t)t+t,tetft�t�t�tu	u
uuuuuu����������įĞ��x�jWD�$h�"ihi=5�B*OJQJ^Jph$h�"ih�"i5�B*OJQJ^Jphh�"iB*OJQJ^Jph!h�"ihi=B*OJQJ^Jph(h�"ihi=0J#6�B*OJQJ^Jph!hi=hi=B*OJQJ^Jph(h�"ihi=0J>*B*OJQJ^Jph�!jh�"ihi=OJQJU^Jh�"ihi=OJQJ^J!jh�"ih�"iOJQJU^Jh�"ih�"iOJQJ^Ju!u%u;ucuhujuku�u�u�v�v�v�v�v�v�v�v�v�v��˾�˗˗���m�Z�L9�$h;y�h;y�5�B*OJQJ^Jphh;y�B*OJQJ^Jph$h;y�h!APB*OJQJ\�^Jph(h;y�h!AP0J#6�B*OJQJ^Jph(h;y�h!AP0J>*B*OJQJ^Jph*jh;y�h!APB*OJQJU^Jph!h;y�h� YB*OJQJ^Jphh;y�h;y�OJQJ^J!h;y�h!APB*OJQJ^Jph!h!APh!APB*OJQJ^Jph$h!APh!APB*OJQJ\�^Jph�v�v�v�v�v�v�v w!wQwTw�w�w�w�w�w�w�w�w�w�w��Ͼܨܨ�}��lWl�lI6l$h;y�h;y�5�B*OJQJ^Jphh;y�B*OJQJ^Jph(h;y�htE�0J#6�B*OJQJ^Jph!htE�htE�B*OJQJ^Jph+h;y�htE�0J>*B*OJQJ\�^Jph(h;y�htE�0J>*B*OJQJ^Jph*jh;y�htE�B*OJQJU^Jph!h;y�h� YB*OJQJ^Jphh;y�h;y�OJQJ^J!h;y�htE�B*OJQJ^Jph$h;y�htE�B*OJQJ\�^Jph�w�w�w�w�wIxJxRxSxUxVx�x�x�x�x�x�x=y>yFyGyNyOyPyQy�y�y�y�y�y�y�y�y�y�yzzz��Ͼ������������������܌܌wawawawaw��+h�\jh�\j0J>*B*OJQJ\�^Jph(h�\jh�\j0J>*B*OJQJ^Jph*jh�\jh�\jB*OJQJU^Jphhx�hx�0JOJQJ^Jhx�hx�OJQJ^J!jhx�hx�OJQJU^Jhx�h�\jOJQJ^J!h�\jh�\jB*OJQJ^Jph$h�\jh�\jB*OJQJ\�^Jph%zzzzzz z*z-z:z;ztzuz�z�z�z{{���ڻ�ڕ�n�nYn�D6hmR�B*OJQJ^Jph(hmR�hU0J#6�B*OJQJ^Jph(h�-�hU0J>*B*OJQJ^Jph*jh�-�hUB*OJQJU^Jph!h�-�hUB*OJQJ^Jph$h�-�hUB*OJQJ\�^Jph$hx�h�\j5�B*OJQJ^Jphhx�B*OJQJ^Jph!hx�h�\jB*OJQJ^Jph!h�\jh�\jB*OJQJ^Jph(hx�h�\j0J#6�B*OJQJ^Jph{{{
{{{{3{S{U{V{�{�{�{�{||
|||��ϼݩ���t�t_I_t�4�(hmR�h	ug0J#6�B*OJQJ^Jph+h�-�h	ug0J>*B*OJQJ\�^Jph(h�-�h	ug0J>*B*OJQJ^Jph*jh�-�h	ugB*OJQJU^Jphh�CJOJQJ^JaJ!h�-�h	ugB*OJQJ^Jph$h�-�h	ugB*OJQJ\�^Jph$hmR�hmR�5�B*OJQJ^JphhmR�B*OJQJ^Jph!h�-�hUB*OJQJ^Jph!hmR�hUB*OJQJ^Jph|||||)|=|F|V|y|{|||�|�|5}6}7}G}H}L}M}��ϼݫ����u�u`u�K8�$hmR�h	ug6�B*OJQJ^Jph(hmR�h	ug0J#6�B*OJQJ^Jph(h�{h	ug0J>*B*OJQJ^Jph*jh�{h	ugB*OJQJU^Jphh�{h�{OJQJ^J$h�{h	ugB*OJQJ\�^Jph!h�{h	ugB*OJQJ^Jph$h�h�5�B*OJQJ^Jphh�B*OJQJ^Jph!h�-�h	ugB*OJQJ^Jph!hmR�h	ugB*OJQJ^JphM}N}Q}[}h}�}�}�}�}�}�}�}�}'~*~q~r~��ʷ���w�a�aL6La+h�Jh1k90J>*B*OJQJ\�^Jph(h�Jh1k90J>*B*OJQJ^Jph*jh�Jh1k9B*OJQJU^Jph!h�Jh� YB*OJQJ^Jph!h�Jh�JB*OJQJ^Jphh�Jh�JOJQJ^J!h�Jh1k9B*OJQJ^Jph$h�Jh1k9B*OJQJ\�^Jph!h�{h	ugB*OJQJ^Jph$h�{h�{5�B*OJQJ^Jph!h�{h�{B*OJQJ^Jphr~s~�~�~�~�~�~�~�~�~�~�~�~�~�~�~��Ƶ��lWlWF1)jh�D�h�D�CJOJQJU^JaJ h�D�h�-�CJOJQJ^JaJ)h�-�h�-�B*CJOJQJ^JaJph,h�-�h�-�B*CJOJQJ\�^JaJph$h�Jh1k95�B*OJQJ^Jphh�JB*OJQJ^Jph!hmR�h�D�B*OJQJ^Jph!hmR�h1k9B*OJQJ^Jph$h�Jh1k96�B*OJQJ^Jph(hmR�h1k90J#6�B*OJQJ^Jph!h�-�h1k9B*OJQJ^Jph�~"#%&�����������!�$�&�'�`�a�׀؀ـ݀ހ�����������������ɻ�������s[/hmR�h�-�5�6�B*CJOJQJ^JaJph0hmR�h�-�0J#6�B*CJOJQJ^JaJph2jh�-�h�-�B*CJOJQJU^JaJph)h�-�h�-�B*CJOJQJ^JaJphh� YB*OJQJ^Jph h�D�h� YCJOJQJ^JaJ)jh�D�h�D�CJOJQJU^JaJ h�D�h�D�CJOJQJ^JaJހ�������
�z�{�������������������n�o�x�y�{�������ì՗�q`q`q`q`q`q`q`q`q`O� hf�h� YCJOJQJ^JaJ hf�hf�CJOJQJ^JaJ)jhf�hf�CJOJQJU^JaJ hf�h�8�CJOJQJ^JaJ)h�K�h�8�B*CJOJQJ^JaJph,h�D�h�D�5�B*CJOJQJ^JaJph#h�D�B*CJOJQJ^JaJph)h�-�h�-�B*CJOJQJ^JaJph)hmR�h�-�B*CJOJQJ^JaJph��������a�b�c�g�h�l�n�p�{������������ ��������Ѹ���u�dWF9F9F9F9hI5�hI5�OJQJ^J!jhI5�hI5�OJQJU^JhI5�h�K�OJQJ^J!h�K�h�K�B*OJQJ^Jph,hf�h�8�5�B*CJOJQJ^JaJph)h"~"h�8�B*CJOJQJ^JaJph,h"~"h�8�6�B*CJOJQJ^JaJph0h"~"h�8�0J#6�B*CJOJQJ^JaJph)h�K�h�8�B*CJOJQJ^JaJph2jh�K�h�8�B*CJOJQJU^JaJph�{������/�����	�S�љ~�&�����������oo$
&F-DM�
����a$gde]�!$
&Fa$gd�l�$$
&F-DM�
����a$gd�;c$
&F-DM�
����a$gd�G�2$
&F-DM�
����a$gd�G�!$
&Fa$gd�]�$
&Fa$gd�]�!$
&Fa$gd�K�2$
&F-DM�
����a$gd�K����������������������T�U�ԅՅօ�������������������Ƶ������u�d�VC�$h�^�h�^�5�B*OJQJ^Jphh�^�B*OJQJ^Jph!h"~"h�K�B*OJQJ^Jph(h"~"h�K�0J#6�B*OJQJ^Jph(h�K�h�K�0J>*B*OJQJ^Jph*jh�K�h�K�B*OJQJU^Jph!h�K�h�K�B*OJQJ^Jphh� YB*OJQJ^JphhI5�h� YOJQJ^JhI5�hI5�OJQJ^J!jhI5�hI5�OJQJU^J����f�g�o�p�r�s�����������i�j�u�v�x�y�����������m�n�w�x�z�{��������������ٵ������������sfsfsfsfsfsfsfsfsfhU{+hU{+OJQJ^J!jhU{+hU{+OJQJU^J(hU{+h�Rg0J>*B*OJQJ^Jph�hU{+h�Rg0JOJQJ^JhU{+h�RgOJQJ^J!jhU{+h�RgOJQJU^J%h�]�h�Rg0JB*OJQJ^Jph!h�]�h�RgB*OJQJ^Jph*jh�]�h�RgB*OJQJU^Jph%���a������������	�
��
���!�;���վ����Մ�vc�R?.!h�]�h�~B*OJQJ^Jph$h�]�h�~B*OJQJ\�^Jph!h�]�h	ugB*OJQJ^Jph$h�^�h�^�5�B*OJQJ^Jphh�^�B*OJQJ^Jph!h�S�h�RgB*OJQJ^Jph+h�S�h�Rg0J6�>*B*OJQJ^Jph$h�S�h�Rg6�B*OJQJ^Jph-jh�S�h�Rg6�B*OJQJU^Jph!h�]�h�RgB*OJQJ^JphhU{+h�RgOJQJ^JhU{+h� YOJQJ^J;�<�u�v�݊ފߊ��������� �!�Z�[������ٯِٞ}�jYCYC*jh�]�h�M9B*OJQJU^Jph!h�]�h�M9B*OJQJ^Jph$h�]�h�M9B*OJQJ\�^Jph$h�^�h�^�5�B*OJQJ^Jphh�^�B*OJQJ^Jph!h�S�h�~B*OJQJ^Jph(h�S�h�~0J#6�B*OJQJ^Jph(h�]�h�~0J>*B*OJQJ^Jph!h�]�h�~B*OJQJ^Jph*jh�]�h�~B*OJQJU^Jph[������#�$�%�'�/�;�=�H�J�R�S���įġġ��wbwbQ<)jh�^�h�^�CJOJQJU^JaJ h�^�h�]�CJOJQJ^JaJ)h�]�h�]�B*CJOJQJ^JaJph,h�]�h�]�B*CJOJQJ\�^JaJph$h�S�h�S�5�B*OJQJ^Jphh�S�B*OJQJ^Jph(h�S�h�M90J#6�B*OJQJ^Jph!h�]�h�M9B*OJQJ^Jph*jh�]�h�M9B*OJQJU^Jph(h�]�h�M90J>*B*OJQJ^JphS�����ƌnjɌʌ;�<�E�F�H�I�����Íōʍ͍̍��i�j�k�{�|����������������������ɴ�������jU�)h�S�h�]�B*CJOJQJ^JaJph,h�^�h�]�6�B*CJOJQJ^JaJph0h�S�h�]�0J#6�B*CJOJQJ^JaJph2jh�]�h�]�B*CJOJQJU^JaJph)h�]�h�]�B*CJOJQJ^JaJph h�^�h� YCJOJQJ^JaJ)jh�^�h�^�CJOJQJU^JaJ h�^�h�^�CJOJQJ^JaJ���������������	�
��
�|�}����������������������r�����r��aTa?aT(h?vPh�G�0J>*B*OJQJ^Jph�h?vPh�G�OJQJ^J!jh?vPh�G�OJQJU^J%h?vPh�G�0JB*OJQJ^Jph!h?vPh�G�B*OJQJ^Jph*jh?vPh�G�B*OJQJU^Jph)h�G�h�]�B*CJOJQJ^JaJph)h�]�h�]�B*CJOJQJ^JaJph,h�^�h�^�5�B*CJOJQJ^JaJph#h�^�B*CJOJQJ^JaJph��u�v�������������������i�j�p�q�s�u�x�����e�f�p�q�r�v�x��������������������ò���r��aN$h?vPh?vP6�B*OJQJ^Jph!h�S�h�G�B*OJQJ^Jph+h�S�h�G�0J6�>*B*OJQJ^Jph$h�S�h�G�6�B*OJQJ^Jph-jh�S�h�G�6�B*OJQJU^Jph!h?vPh�G�B*OJQJ^Jph!h?vPh� YB*OJQJ^Jphh?vPh� YOJQJ^Jh?vPh]PsOJQJ^J!jh?vPh]PsOJQJU^Jx�z����������������r�s�y�z�|�}��������8�J�S�������ӽ�������������������{�jWjLh?vPh�G�B*ph%h?vPh�G�0JB*OJQJ^Jph!h?vPh�G�B*OJQJ^Jph!h�N�h� YB*OJQJ^Jphh�N�h�N�OJQJ^J%h�N�h�G�0JB*OJQJ^Jph!h�N�h�G�B*OJQJ^Jph*jh�N�h�G�B*OJQJU^Jph!h?vPh?vPB*OJQJ^Jphh?vPh?vPOJQJ^Jh?vPh?vP5�OJQJ^J�������������������	���)�*�������������ij���{fU@/@/ h�Y�h�Y�CJOJQJ^JaJ)jh�Y�h�Y�CJOJQJU^JaJ h�Y�h�;cCJOJQJ^JaJ)h�d�h�;cB*CJOJQJ^JaJph,h�d�h�;cB*CJOJQJ\�^JaJph$h�N�h�G�5�B*OJQJ^Jphh�N�B*OJQJ^Jph!h?vPh�G�B*OJQJ^Jph!h�S�h�G�B*OJQJ^Jph$h�S�h�G�6�B*OJQJ^Jph-jh�S�h�G�6�B*OJQJU^Jph����������$�%�'�(�����������������������4�5�6�B���������������ȷ�����q��\C0h�Y�h�;c0J#6�B*CJOJQJ^JaJph)h�d�h�;cB*CJOJQJ^JaJph,h96h�;cB*CJOJQJ\�^JaJph2jh96h�;cB*CJOJQJU^JaJph)h96h�;cB*CJOJQJ^JaJph h�Y�h�;cCJOJQJ^JaJ h�Y�h� YCJOJQJ^JaJ h�Y�h�Y�CJOJQJ^JaJ)jh�Y�h�Y�CJOJQJU^JaJB�C�G�H�I�K�S�{�}�~���������d�e�l�m�o�p����������������ìꛎ}p}p}p}p}p}p}p}p}pbT�h� YB*OJQJ^Jphh�l�B*OJQJ^Jphh�l�h�l�OJQJ^J!jh�l�h�l�OJQJU^Jh�l�h�;cOJQJ^J!h�h�;cB*OJQJ^Jph,h�Y�h�;c5�B*CJOJQJ^JaJph#h�Y�B*CJOJQJ^JaJph)h�S�h�;cB*CJOJQJ^JaJph)h�d�h�;cB*CJOJQJ^JaJph��@�A�����������řƙǙəљҙD�E�Q�R�T�U�ĚŚΚϚњ�����ٯِٞ}�gVgCgVgVgCgV%h*�h�;c0JB*OJQJ^Jph!h*�h�;cB*OJQJ^Jph*jh*�h�;cB*OJQJU^Jph$h�l�h�;c5�B*OJQJ^Jphh�l�B*OJQJ^Jph!h�l�h�;cB*OJQJ^Jph(h�l�h�;c0J#6�B*OJQJ^Jph(h�h�;c0J>*B*OJQJ^Jph!h�h�;cB*OJQJ^Jph*jh�h�;cB*OJQJU^JphњҚB�C�K�L�N�s�x���e�f�j�k�l�p�q�r�t�}�~����������̾�������٭ub�uQDQh�;che]�OJQJ^J!jh�;che]�OJQJU^J$h:k�h:k�5�B*OJQJ^Jphh�;cB*OJQJ^Jph$h:k�h�;c6�B*OJQJ^Jph-jh:k�h�;c6�B*OJQJU^Jph!h*�h�;cB*OJQJ^Jphh� YB*OJQJ^Jphh:k�h:k�OJQJ^J!h:k�h�;cB*OJQJ^Jph*jh:k�h�;cB*OJQJU^Jph����������p�q�{�|�~�����������e�f�m�n�p�q�������]�^�e�f�h�j�m�n�o�����˾˾��˾˾��˱�������������������x�g�!h�;ch�;cB*OJQJ^Jphh� YB*OJQJ^Jphh:k�h� YOJQJ^Jh:k�h:k�OJQJ^J!jh:k�h:k�OJQJU^Jh:k�he]�OJQJ^Jh�;che]�OJQJ^J!jh�;che]�OJQJU^J(h�;che]�0J>*B*OJQJ^Jph�h�;che]�0JOJQJ^J'����
���������%�&�5�W�{���������������������}l^Pl:l:*jh�P�h�;cB*OJQJU^Jphh� YB*OJQJ^Jphh:k�CJOJQJ^JaJ!h�P�h�;cB*OJQJ^Jph$h�P�h�;cB*OJQJ\�^Jphh�;che]�h:k�h:k�5�OJQJ^Jh:k�OJQJ^Jh:k�he]�OJQJ^Jh�;che]�OJQJ^J+h:k�he]�0J6�>*B*OJQJ^Jph�h:k�he]�6�OJQJ^J$jh:k�he]�6�OJQJU^J��J�K�L�[�\�`�a�b�d�m�n�o��������įĞĐ}�o^P^?,$h:k�h*�6�B*OJQJ^Jph!h�8h*�B*OJQJ^Jphh�lyB*OJQJ^Jph!h�;ch*�B*OJQJ^Jphh�;cB*OJQJ^Jph$h:k�h�;c5�B*OJQJ^Jphh:k�B*OJQJ^Jph!h:k�h�;cB*OJQJ^Jph(h:k�h�;c0J#6�B*OJQJ^Jph!h�P�h�;cB*OJQJ^Jph*jh�P�h�;cB*OJQJU^Jph(h�P�h�;c0J>*B*OJQJ^Jph&�n�.�����������;�'���@��
������������~~~$
&Fdh-DM�
����a$gd��$
&F-DM�
����a$gd��2$
&F-DM�
����a$gd�L�1$
&Fa$gd�M[$
&Fa$gd�M[ $
&Fa$gd�M[$
&Fa$gd�8 $
&Fa$gd�8 $
&Fa$gd�;c��!�"�$�-�.�E�O�P�����ŢƢȢɢ8�9�B�C�E�F�������£ģɣңy�������������������������������l�[!h�lyh*�B*OJQJ^Jph$h�lyh*�6�B*OJQJ^Jphh�lyh*�0JOJQJ^Jh�lyh�lyOJQJ^J!jh�lyh�lyOJQJU^Jh�lyh*�OJQJ^J!h�8h�;cB*OJQJ^Jph$h:k�h*�5�B*OJQJ^Jph!h:k�h*�B*OJQJ^Jph!h�8h*�B*OJQJ^Jph ����������������� ����������������
������ܳ�����~q~b~q~q~M~q@h�lyh�lyOJQJ^J(h�lyh�80J>*B*OJQJ^Jph�h�lyh�80JOJQJ^Jh�lyh�8OJQJ^J!jh�lyh�8OJQJU^J%h�8h�80JB*OJQJ^Jph!h�8h�8B*OJQJ^Jph*jh�8h�8B*OJQJU^Jph$h�lyh*�5�B*OJQJ^Jph!h�8h*�B*OJQJ^Jph$h96h*�5�B*OJQJ^Jph��}�~��������������������p�q�{�|�~�����:�;��������������������������������������Ƶ���u��dV�Vh�lyB*OJQJ^Jph!h�lyh�8B*OJQJ^Jph+h�lyh�80J6�>*B*OJQJ^Jph$h�lyh�86�B*OJQJ^Jph-jh�lyh�86�B*OJQJU^Jph!h�8h�8B*OJQJ^Jphh� YB*OJQJ^Jphh�lyh� YOJQJ^Jh�lyh�lyOJQJ^J!jh�lyh�lyOJQJU^J��������ȨʨѨݨ������A�B�����������������������λ�������j�jUj�@�����(h�lyhZ�0J#6�B*OJQJ^Jph(hZ�hZ�0J>*B*OJQJ^Jph*jhZ�hZ�B*OJQJU^Jphh� YB*OJQJ^Jphh�lyB*OJQJ^Jphh�lyCJOJQJ^JaJ!hZ�hZ�B*OJQJ^Jph$hZ�hZ�B*OJQJ\�^Jphh�8B*OJQJ^Jph!h�8h�8B*OJQJ^Jph$h�lyh�ly5�B*OJQJ^Jph����*�+�7�8�:�;�������������#�$�+�,�.�/����������������������������������������������ٚ��q��`Rh��B*OJQJ^Jph!h��hZ�B*OJQJ^Jph+h��hZ�0J6�>*B*OJQJ^Jph$h��hZ�6�B*OJQJ^Jph-jh��hZ�6�B*OJQJU^Jph(hZ�hZ�0J>*B*OJQJ^Jph%hZ�hZ�0JB*OJQJ^Jph!hZ�hZ�B*OJQJ^Jph*jhZ�hZ�B*OJQJU^Jph ���������� �!�'�(�*�+��������������������������������������θ���������������raTaTaTaTaTah��h��OJQJ^J!jh��h��OJQJU^Jh��h�M[OJQJ^J%h�M[h�M[0JB*OJQJ^Jph(h�M[h�M[0J>*B*OJQJ^Jph!h�M[h�M[B*OJQJ^Jph*jh�M[h�M[B*OJQJU^JphhZ�B*OJQJ^Jph!hZ�hZ�B*OJQJ^Jph$h��h��5�B*OJQJ^Jph �
��z�{����������	�
������$�*�-�7�9�X���������ıĠĒ�n�]�L; h��h��CJOJQJ^JaJ!h��h��B*OJQJ^Jph!h��hE`�B*OJQJ^Jph!h��h� YB*OJQJ^Jph$h��h��5�B*OJQJ^Jphh��B*OJQJ^Jph!h��h�M[B*OJQJ^Jph$h��h��6�B*OJQJ^Jph!h�M[h�M[B*OJQJ^Jphh��h� YOJQJ^J!jh��h��OJQJU^Jh��h��OJQJ^JX�^�а԰ٰ۰ݰ���[�\�g�h�j�k�ٱڱ����a�b����ݹ�ݘ�݂o�݂݂o��^Q^h��h�M[OJQJ^J!jh��h�M[OJQJU^J%h��h�M[0JB*OJQJ^Jph*jh��h�M[B*OJQJU^Jphh��B*OJQJ^Jph$h��h��5�B*OJQJ^Jph!h��h��B*OJQJ^Jph$h��h�M[6�B*OJQJ^Jph!h��h�M[B*OJQJ^Jph!h��hE`�B*OJQJ^Jphb�r�s�u�v�������m�n������������������^�_���(�)�*�/���ͼ������������������͑zgzQzg�+h��h�M[0J6�>*B*OJQJ^Jph$h��h�M[6�B*OJQJ^Jph-jh��h�M[6�B*OJQJU^Jph!h��h�M[B*OJQJ^Jphh��hE`�OJQJ^Jh��h��OJQJ^J!jh��h��OJQJU^Jh��h�M[OJQJ^J!jh��h�M[OJQJU^J(h��h�M[0J>*B*OJQJ^Jph�/�0�2�;�?�D�S�j�o�q�r�����������Ͷ��{f�L�L�L�23h=[lh�L�0J#6�B*CJOJQJ\�^JaJph2jh=[lh�L�B*CJOJQJU^JaJph)h=[lhE`�B*CJOJQJ^JaJph h=[lh=[lCJOJQJ^JaJ)h=[lh�L�B*CJOJQJ^JaJph)h�L�h�L�B*CJOJQJ^JaJph,h�L�h�L�B*CJOJQJ\�^JaJph!h��h�M[B*OJQJ^Jph$h��h��5�B*OJQJ^Jphh��B*OJQJ^Jph������'�(��������������
���p�{�����Կ����o�\�o�o�\�oI8o!h~h��B*OJQJ^Jph$h~h966�B*OJQJ^Jph%h��h��0JB*OJQJ^Jph!h��h��B*OJQJ^Jph*jh��h��B*OJQJU^Jph,h=[lh=[l5�B*CJOJQJ^JaJph#h=[lB*CJOJQJ^JaJph)h�L�h�L�B*CJOJQJ^JaJph)h=[lh�L�B*CJOJQJ^JaJph,h=[lh966�B*CJOJQJ^JaJph�������������������������������+�,�0�2�4�5���͹�����������l�X�D�'h~h��0J.OJQJ]�^JmH	sH	'h~h��0J-OJQJ]�^JmH	sH	$h~h��0J,OJQJ^JmH	sH	$h<X
h��0J,OJQJ^JmH	sH	'h<X
h��0J+OJQJ]�^JmH	sH	$h<X
h��0J)OJQJ^JmH	sH	'h<X
h��0J*OJQJ]�^JmH	sH	!h��h��B*OJQJ^Jph$h~h~5�B*OJQJ^Jphh~B*OJQJ^Jph5�9�:�>�?�@�R�T�`�b�r�t�y�{���������	�
�
��������ر�؝؝؝؉�v�b�N����ر'h~h��0J.OJQJ]�^JmH	sH	'h~h��0J-OJQJ]�^JmH	sH	$h~h��0J,OJQJ^JmH	sH	'h<X
h��0J+OJQJ]�^JmH	sH	'h<X
h��0J*OJQJ]�^JmH	sH	$h<X
h��0J)OJQJ^JmH	sH	'h<X
h��0J0OJQJ]�^JmH	sH	$h<X
h��0J)OJQJ^JmH	sH	'h<X
h��0J/OJQJ]�^JmH	sH	�%�'�7�9�C�E�F�������������9�:�L�M�O�P�ʺ˺ߺ�����������������Ŵ�����������������œkXk$h~h�0J,OJQJ^JmH	sH	'h96h�0J)6�OJQJ^JmH	sH	'h<X
h�0J+OJQJ]�^JmH	sH	'h~h�0J+OJQJ]�^JmH	sH	h~h~OJQJ^J!jh~h~OJQJU^J$h~h�0J)OJQJ^JmH	sH	$h<X
h�0J)OJQJ^JmH	sH	'h<X
h�0J*OJQJ]�^JmH	sH	�����������
���� �%�'�(��������������������������������ׯכׇs�s�sbUbUbUbUbUbUbUbUbUh~h~OJQJ^J!jh~h~OJQJU^J'h96h�rT0J)6�OJQJ^JmH	sH	'h96h�rT0J*OJQJ]�^JmH	sH	'h96h�0J0OJQJ]�^JmH	sH	'h96h�0J/OJQJ]�^JmH	sH	'h~h�0J.OJQJ]�^JmH	sH	'h96h�0J)6�OJQJ^JmH	sH	'h~h�0J-OJQJ]�^JmH	sH	 ��������н�\�^�_�h�i�m�o�q�s���ï����t`L�8�'h~h�rT0J.OJQJ]�^JmH	sH	'h~h�rT0J-OJQJ]�^JmH	sH	'h96h�rT0J)5�OJQJ^JmH	sH	$h96h960J,OJQJ^JmH	sH	$h96h�rT0J,OJQJ^JmH	sH	$h96h�rT0J)OJQJ^JmH	sH	U'h<X
h�rT0J+OJQJ]�^JmH	sH	'h96h�rT0J+OJQJ]�^JmH	sH	'h96h�rT0J)6�OJQJ^JmH	sH	'h96h~0J)6�OJQJ^JmH	sH	brosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-893.
Liaw YF.  HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/23673137" Reversal of cirrhosis: An achievable goal of hepatitis B antiviral therapy. J Hepatology 2013. doi:pii: S0168-8278(13)00333-4. 10.1016/j.jhep.2013.05.007. [Epub ahead of print].
Buskin SE, Barash EA, Scott JD, Aboulafia DM, Wood RW. Hepatitis B and C infection and liver disease trends among human immunodeficiency virus-infected individuals. World J Gastroenterology 2011;17:1807-16.









 PAGE   \* MERGEFORMAT 1




s�v�w�z�{�|�������������
������ijĠ�y�ydy�O:�(h~h960J#6�B*OJQJ^Jph(h~h<X
0J#6�B*OJQJ^Jph(h�
�h<X
0J>*B*OJQJ^Jph*jh�
�h<X
B*OJQJU^Jph!h�
�h<X
B*OJQJ^Jph$h�
�h<X
B*OJQJ\�^Jph!h~0J0OJQJ]�^JmH	sH	'h96h�rT0J0OJQJ]�^JmH	sH	$h96h�rT0J)OJQJ^JmH	sH	'h96h�rT0J/OJQJ]�^JmH	sH	
�|�s�B�C�E�F�H�I�K�L�N�O�k�l�m�n�o������������������$a$gd�M$dha$ $
&Fdh-DM�
����a$gd�
� $
&Fdh-DM�
����a$gdi=$
&Fdha$gd�rT�� �O�S�q�r�s�������0�1�5�6�8�@�A�B���˸˧����s`�O�<���$h�hi=5�B*OJQJ^Jph!h�hi=B*OJQJ^Jph$h�h966�B*OJQJ^Jphh96B*OJQJ^Jphh�B*OJQJ^Jph!h�
�hi=B*OJQJ^Jphh�
�h�
�!h�
�h�
�B*OJQJ^Jph$h�
�h]�B*OJQJ\�^Jph!h�
�h]�B*OJQJ^Jph!h�
�h<X
B*OJQJ^Jph$h~h<X
B*OJQJ\�^JphB�C�D�F�G�I�J�L�M�O�P�g�h�i�j�m�n�o������������������h�=[mHnHuh�n�jh�n�Uh�d�jh�d�U)h�d�h��B*OJQJ^JmH	phsH	,1�h��/ ��=!�"�#��$��%�������^3���������666666666vvvvvvvvv666666>666666666666666666666666666�6666666666�666666666666hH66666666666666666666666666666666666666666666666666666666666666666�62���� 0@P`p������2(�� 0@P`p������ 0@P`p������ 0@P`p������ 0@P`p������ 0@P`p������ 0@P`p��8X�V~_HmH	nH	sH	tH	@`�@NormalCJ_HaJmH	sH	tH	l@l	Heading 1!$$d��7$8$@&H$a$6�OJQJ]�^JaJmH	sH	Z@Z(�H�	Heading 3$���<@&5�CJOJPJQJ\�^JaJDA`�DDefault Paragraph FontVi�V
0Table Normal :V�4�4�
la�(k �(
0No List`B@�`	Body Textd��7$8$H$6�CJOJQJ]�aJmH	sH	dP@dBody Text 2$d��7$8$H$a$CJOJQJaJmH	sH	dQ@dBody Text 3$d��7$8$H$a$OJQJ^JaJmH	sH	.X`�!.c!�@Emphasis6�]�*�O�1*c!�	highlightR�OBRc!�Body Text 21$a$OJQJaJmH	sH	tH
4@R4�M0Header

�H�$6��a6�M0Header CharCJaJ4 r4
�M0Footer

�H�$6��6�M0Footer CharCJaJH�@�H
� �0Balloon TextCJOJQJ^JaJN��N� �0Balloon Text CharCJOJQJ^JaJ4U@�4	e]�0	Hyperlink	>*ph�.�O��.�v�ref-journal&�O��&�v�ref-vol$���$�v�nowrap.�O��.*�fulltext-it4�O4�P�title �d�d[$\$2�O2�P�desc!�d�d[$\$8�"8�P�details"�d�d[$\$ �O�1 �P�jrnl0�OB0Ltitle1$CJaJ.�OR.Ldesc1%CJaJ4�Ob4Ldetails1&CJaJB^rB	"i0Normal (Web)'�d�d[$\$R��R�H�Heading 3 Char5CJOJPJQJ\^JaJ0a@�0	l�0	HTML Cite6�]�$�O��$l�author0�O��0l�articletitle8�O�8l�
journaltitle36�]�&�O��&l�pubyear&�O��&l�vol35�\�*�O��*l�	pagefirst(�O�(l�pagelastF�OF��fulltext-author
1�d�h[$.�O".�-�desc22CJaJPK!����[Content_Types].xml���N�0E�H���-J��@%�ǎǢ|�ș$�ز�U��L�TB� l,�3��;�r��Ø��J��B+$�G]��7O٭V��<a���(7��I��R�{�pgL�=��r���8�5v&����uQ�뉑8��C����X=��$␴�?6N�JC������F�B.ʹ'�.�+���Y�T���^e5�5�� ��ð�_�g -�;�����Yl�ݎ��|6^�N��`�?���[��PK!�֧�6_rels/.rels���j�0���}Q��%v/��C/�}�(h"���O�
����=������ ����C?�h�v=��Ʌ��%[xp��{۵_�Pѣ<�1�H�0���O�R�Bd���JE�4b$��q_����6L�R�7`������0̞O��,�En7�Li�b��/�S���e��е�����PK!ky���theme/theme/themeManager.xml�M
� @�}�w��7c�(Eb�ˮ��C�AǠҟ����7��՛K
Y,�
�e�.���|,���H�,l����xɴ��I�sQ}#Ր���� ֵ+�!�,�^�$j=�GW��)�E�+&
8���PK!0�C)��theme/theme/theme1.xml�YOo�6��w toc'vu�ر�-M�n�i���P�@�I}��úa��m�a[�إ�4�:lЯ�GR��X^�6؊�>$�������!)O�^�r�C$�y@�����/�yH*��񄴽)�޵��߻��UDb�`}"�qۋ�Jח���X^�)I`n�E���p)���li�V[]�1M<������O�P��6r�=���z�gb�Ig��u��S�eb��O������R�D۫����qu	�g��Z����o~ٺlAp�lx�pT0���+[}`j���zA��V�2�F���i�@�q�v�֬5\|��ʜ̭N��le�X�ds���jcs���7���f����
��W��+�Ն�7����`���g�Ș��J���j|��h(�K��D-����
dX��iJ�؇(��x$(��:��;�˹!�I_�T��S1�����?E��?�����?ZBΪm���U/������?�~����xY���'���y5�g&΋/����ɋ�>���G�M�Ge���D�����3Vq%'#q�����$�8��K�����)f�w9:ĵ��
x}r�x����w���r�:\TZaG�*�y8I�j�bR��c|XŻ�ǿ�I
u3KG�nD1�NIB�s���
��R��u���K>V�.EL+M2�#'�f��i~�V��vl�{u8��z��H�
�*���:�(W�☕
~��J�T�e\O*�tHG��HY��}KN�P�*ݾ˦���TѼ�9/#��A7�qZ��$*c?���qU��n��w�N��%��O��i�4=3��N���)cbJ
u�V�4����(Tn���
7��_?���m-ٛ�{U���B�w�<w���_���$�#��[Ի�8{���(�/�$Ϫ0h݋�F۴��®{L�)#7�i�%�=A�:s�$�),��Qg20pp��f
\}DU4�p
M{��DB��%J������+{�l�C���]��=��5
2F��hsF+��Y��\Ɉ�n�ì��:3���E�[��6�9����`��&45Z!��*��5k8�`Fmw��-��"�d>�z��n���ʜ"Z��x��J�Z��p;�������{/�<�P;��,)''K�Q�k5���q��pN��8�K�Gb�e���
�S��d�̛�\17	�p�a�>��SR!���

3��K4'+�r�zQ
TT��I����Ivt]K�c⫲�K#�v�5+�|��D������~��O@%\w���_�nN[�L��9K���q��g�V�h��n
R!�y+��U�n�;�*&�/H�r��T�	�>��>\
�t��=.Tġ
���S; Z�~�!����P��9gi���C�ڧ!�#	B��,��;�X=ۻ,I�2UW�V�9$l�k���=A��j���;�{�A�P79�|s*Y�����;�̠�[�MC�ۿ�hf��]o��{oY=1k�yV��V���5E8�Vk+֜���\8���0X4D)�!!��?*|f�v�
u���"�x��A�@T_������q��6�4)kڬu�V�7��t�'��%;���i�9s�9�x���,��ڎ-45x�d���8?�ǘ�d�/Y|t��&LIL�J`�& �-G�t�/��PK!
ѐ��'theme/theme/_rels/themeManager.xml.rels��M
�0���wooӺ�&݈Э���5
6?$Q��
�,.�a��i����c2�1h�:�q��m��@RN��;d�`��o7�g�K(M&$R(.1�r'J��ЊT���8��V�"��AȻ�H�u}��|�$�b{��P����8�g/]�QAsم(����#��L�[������PK-!����[Content_Types].xmlPK-!�֧�60_rels/.relsPK-!ky���theme/theme/themeManager.xmlPK-!0�C)���theme/theme/theme1.xmlPK-!
ѐ��'�	theme/theme/_rels/themeManager.xml.relsPK]�
<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<a:clrMap xmlns:a="http://schemas.openxmlformats.org/drawingml/2006/main" bg1="lt1" tx1="dk1" bg2="lt2" tx2="dk2" accent1="accent1" accent2="accent2" accent3="accent3" accent4="accent4" accent5="accent5" accent6="accent6" hlink="hlink" folHlink="folHlink"/>�������	*****-�	�
&
r
���6�c�=���!,%q&�'�),w->/�/�0<2o3�4�5m8s9�:u;�;�=D?�?�A\BeD�EXFjHdJ�K�LNNaO#P�Q�R�S%V�V�X�Y5[N]�^k_S`{b�c!e@f�h2jql�m`nr�su�v�wz{|M}r~�~ހ��������;�[�S����x�����B��њ����������������X�b�/����5������s��B�o�_abcefghijklmnopqstuvwxyz{|}~����������������������������������������������������������������������������������������������9B�\�i�&�
�o�`dr�������;_�_�_�_%`0`3`�`�`Ub�bc�c_dgdjd�d�d�dheoere�e�e�ejf{f~f�f�f}g�g�gh}h�h�hiii�i�i�i�iej�jk�k^l�lmRm�m�m�m;nCnFn�n�n�no�o�o�omp�pq�q�q-r�r-sgs�s&t�t�t�t
uuu�u�u�u�uOv�v�v�v�vkwswvw�w�w�w4x�xy�y�y�yz
zzz�z�z�zL{o{�{�{�{^|l|o|�|�|�|d}r}u}�}�}�}d~p~m{��U���Ҁ��ʁ7�>�A�������0�:�D�~���w���������p�y�|������i�q�t���m�݇���n�z�}����a�h��e�l����� ���������)�c�����c�k�n�܍��c�t�~���2�I���ɏ̏<�F�I���Ð��ݑ���h�t�w�����d�l�o�ݓ��Y�d�g�Քݔ.�������4�–Ǘ5�=�@�������.�9���������������������m�t�w������$����
�/�������!�*�-���������~����&�������������������	�w�������a�Ӧߦ�Q�Z�]�٧��[�c�f������m�x�֩�����#��������������,�5�8���įǯB�W���������������ͳ�S���X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��X��$&-!����8�@�����������0�(	�
��B
�S����	?���7����������xG{GL$L\LaL�Y�Y�Y�Yz^�^_%_*_2_�_�_&`.`DaPaTaZaiauayaa�a�ab
bbb b)b-b2bc%c&c*cKcRcScWc~c�c�c�c�c�c`ded�d�diemetfyf�g�g�g
hii�j�j�j�j�j�j�j�j�j�j�j�j�klmm>mEm�n�n�o�ospwp�p�p�p�p�q�q�q�q�q�q�q�q�q�q�r�r�r�r
ss�s�s�t�tuu�u�u�x�xyyyy�z�zN{R{_|j|�|�|�}�}e~n~t{������
��� �{���������������������Ɓ8�<�1�8�������������q�w�j�o�������އ�o�x���b�f�k�q�̉։׉߉����������������������������Ҍی��ݍ�m�r��!���Ǐ=�D�Ɛ͐ѐܐ��u�}���Z�b�֔۔����������˕ϕؕܕ���ĖȖ���������—6�;�����/�7�X�g�n�r�������n�r���B�G�K�Q�U�`�k�t��������������z�������ť̥Ԧݦڧ�\�a����������������������ǭ̭֭ڭ���C�J�q�x�������������-�3�����C�U������"�����ijȳW�a�h�o�����ƴ̴۴�����������������������
WY#
%
���	�%�%�+�+�.
/�D�DG$GII$K(KOLUL�M�M�S�SmTpT0c3c�q�qC�O�h�l�}�������������������������33333333333333333333
���&��{7{7�H�H	_
_����������
���&��{7{7�H�H	_
_�����P�(����������h
�����^��`����h�H.�h
�����^��`����h�H.�h
�p�L�^�p`�L��h�H.�h
�@���^�@`����h�H.�h
����^�`����h�H.�h
���L�^��`�L��h�H.�h
�����^��`����h�H.�h
�����^��`����h�H.�h
�P�L�^�P`�L��h�H.�P��������									?�
wt�#s��5:l�G�`ClJ��O��x�W�P�	Rr���\�7V\��g�e�lu�40'>z�i�i�p7�R�!P�k�s�1T�N�]�9[g�	�E -�g�=R�e��LOy�q?�u(O� =akX4Ee|""vj�y[��H!qEx	�qk �s�	}Cxh[g�	99:@�[�	�oNxhuk�
�_ I!�
�s�	G?�
_7'Fxc�!,N�x��!�E�_8��(�Qm`t9�j�]�#�f�
k	�w�e�V^`Tuk�
4J^��=�R��H!q3�9�x�0[�X(�R�=l"�"Ee|�yV"���67/,�5��1,UAF�|@F.J��T/r�ajt-�F�y�9��f?3ROd�
=t=2y�0[��Gv�_
�eB~o�_�P�k:��<kPXx�|!�_&,��^�0�7H8�r��q~�MD#�9Vy�_ �qk lpR�� ��oS[� �5�wh�!�K3�yV"�I�bxhl"�"4J^�]#v�d{##U#�t*)]�#sZ�wt�#�X.}~%�j�%�lx�'��3'Yh�f_7';�m�C�'�?,0��(�!P��(�t*)�ra�)*2y�cDm*hU�4SC�*<Go�u�*�929I+�oFS�?`+�4�r7~�+�[C67/,�+�,�y�Vy_s-�G�Po`�-#U#;#�-S[� ��.�(�K:a�.�f�
Sy0�0:`f""�?,0�9/0�#x7�40�V�N�^�0
bqZI]�1�KUl�K3Oy�xh�;+3�~�_�_�3.J��(�3`Zo"�3nF�phU�4�=��4�|�>�B�4B`�jI@�4�e�,�5q~�M�0�5TW�e�
-6�_�37_�6�#xgxhd	74�A\7�� �#x7�MX`�\�7K|f2�7�I�~'}�8�6sm`t9�G+cy�9�e~X�9�qly�U:�e2DG;gie\3<�>�a�|{<�0�5	U�<�qn��<�
�<��2�<|Pl&K=��T
=t=�m�B��=AF�Dv�=�QGaR%>�1T�|�>�^lxh3Y)?Od�qmz?y_s-�l	@G?�
99:@Yg
e�R�@4�AP0�@rm�q_A�jNF4�AAz�I3+B�>!j""�_,B�m�B�[CEx	}C�_82{�C{�WY<�D�[�GSe�D	U�<�E�x'F�!�E�)*|@F�x'F�'�jNF4!aN
�F��t-�FSe�D�QG��.@�G�npg�[�GbZ'R�
�Gi	�jxh0�H^�n�]eIN
�FNUnI3<�{yI09�UAz�IY<�D`ClJ�0�Wxh�p�J�v""��Jy�q_4�J�3'X�J\0�h�(�K�;+3[L�}��L�p7�Q�M�
�<q~�Mg�n�oN�hx�!,N;#�-'<�Nt-�FI�N�
w�V�NB~o�G�P2�7>�P�K3�_�P-U�]
	Q�|�>�GR�a[}�RbZ'R(Of?3R�_,Bz(aR�M�TlpR���*uRcDm*X(�R�j�^�oFS�{yI>>�S�M�T��(	�T�|�>��T#�n�1,U�Q�M"�U4�A09�U�bmlu*�Vw/a�V�
-6�y�VI�NiO�W�9�0�Ws��x�WNUnI{�W@�GfC�X�u�*tSNY�]#�`�Y�ken�4 Z
bqZ
ddY�Z2DG;gie\2{�C-U�]3Y)?�N�]�7HA)�]�j�%�j�^�}3_�~�_�C�'|!�_7~�+�MX`P0�@Q�`}~%�raQ�`4!a>>�Sw/a�`�Y� =a�=R�>�a�P�v�aDv�=OOb�*uR�I�bvj�G+c3v�dz(aRYg
e�h�uOp+e_A
�e	�f�g�eTW�etSNYK|f�{k:`f7_�6��efN
�F	�fYh�f��J�npgkPX�#xgqmz?n~�gV\�-�g�+Yq�Zh\0�hu*�VcU
iv�a�i�i�B�4�>!j�[�	�i	�j'>zB`�j�Zh�{k&K=�^l�5�x�5:l\7|Pl�9/0�KUl�w�bml_4�J�zam;�m�sx�qnA)�]�kenn~�g^�n�}3_g�n>w�t#�n<GoY�Z`ZoaR%>��o��o�!�wnF�p�H!q�O��+Yq�j�rm�q�4 Zy�q	Rr�T/r"�3�.2r�qly'L�r�s�	�4�r2�<8�r:a�.�6s0�H�k�sSy0:�s�_2�t�|{<>w�t'}�8�Y9uYN�yq?�u:�s�u�h�u�Y9u�v�
�G��w�u�hmw�G�""�!�w�k:k	�wsZ�w�Q�lx�zam�hx�GR�sxOp+e�5�xI]�19Vy�qlyo`�-xh�y^`TYN�y�,�zX�J�{�z�x'F�a[}D#��}iO�W�I�~�&,��X.��o&�%f�0�X
o�+6�x�� �5
Q/k���*i9Ml��@�k��C�4�9�	�R�T�Va	�
	z@	$S
<X
�a
�H�F�X	sS'
�A
�J
N\�T�oj��-�lNt�2�A/qw6-�J\M�s��$%�p�')-�A�_�	;$Ij|k�;U�_�!�&7oCo&CHp�/�<�@�{�4ua���U$(�*�/�R��M[v)s� �!�e!3s!jt!"~"l=#!F#�n#�k%�{%8Z&�]&�$'�&'D1'�q'�(!D(�P(:z(;)AI)]O)�b)�*J+�K+U{+,"Q,T,�\,�,�-H-k!-U;-�C-|D->s-�.�k.�/�0L1�>1�g1�2�2D2)2�z3�4U4_=4�F4)N4�z4-5hx59647�=7�8g8�828�78�c8�9�M91k9�
:':
:�%:�5;QO;Q;�e;wP<3a<�l<�=i=(=�/=�>=�B=$J=�S=z=iK>")?%E?�F?�J?�@�
@~@5$@�,@v.@*K@�N@s@�7AfDA�pA�B@Ba#C?C�mC�@DTiD|D;E$.EUDEFE�lE�E�*F�=F�
G@%G�3G�6G�hG�xG�%H�2H�uH�cI�J�WKLF!LemLYM�MN'M�=M�gM�N),ND7NRO=	OQO�>O�`O�!P�'P!AP\BP?vP�AQ�iQ"	R]R\$R6&Rn)R�QR6SRaR8xR�#S:S�sS�tS�S�rT�USU_U�_U�jU�V]V|QV
gVW�$W�X
X�BXCeX�gXoX�Y� Y�ZHZvkZB{ZZq[�=[�M[Q[xZ[�U\�]7^5T^^^�y_�`�	`e<`~`oaB9a�Ma�b�Lb�;cs#e�Fe?^e�f�(f�4f�Rg*tg	ugjheh�kh"i�"i`Ai�j�Ej�\j�xjZk�kuk@k_BkGkLk�Rk�9l=[lwl�n[5nTnPen)oCHp{Mp�]p[~p�q�q�q� qbUq�rq)s�s`s+s�,s]Ps�]sUt+jt�tu�xu"wZ=w�vwww�x�x�x�,xKzx�6y�ly�z�z�z�{q {G{�^{�%|1h|�}�}*N}�~~Y?~�\~]l+�ox��8#��2�
U�F��1��g��}�R$��
��}����3�2r��P��S�Qm��9��k�y��HD��g��
��*�fR�:k��n�^���t��-�yG��V�VW�#��
��A�b�#y�<|������f��0��]��
���b�yv��B�YC����c�o���]K�\��;�d�����0���c7���\%�I�����6��D��v�@�VH��m��	�a4�Z��s����%�lH��O�i�$K�a�����I5�"�u"��J�G��@������a��e��G��s��u����x��W��n�D:��o��r��A��T��-��K�#e�zz���m�l���T<��k�+s���P��[�{7��+�C�F�{L�CA��S��h��}���y��-�mR�>���m�������3H�O��#��%��Z��6��)��1��5�tE�*s�a|���_��7��B��^�s-��@�vN�Q��%��Y�Bc���&��N��b�z�o!��+��M�u���c!�l9������G�!R��v�s�*�3p��{�&X��r�]z�'`��h��
������6��7��N�gn�Y��R��h��#��(�y1��9�`h�l	��-�v�ER��l��o��p�}r�6g�Dt�w�h��8�o�q�s	��L������"��7��D�5J��
�2i��!��0�e]��^������;��<�D��vR�S���6G��r�����I�(�6��f�;�]�,%��W�/c��K�H���?��K�>i��r�/��������|�\��M��r��v���9=�vG�qX�E`��S�d�Ve��$��d��P�NV��v��]�h��"�7�Z;��a�x��W��u���� ��,��R�]�%b�l�7+�=,�!-��5��`�8l�3��o��;�jB�Q�?#��5� =�*h�
��-��Z�e�t3�@��d��#��Q��(��-��v��3��*�;0��I�"v���3�
7�.>�CQ�sW�;y��Z�8l�Ar��P�(R��h/�{w�G�p�c�fO�=M�*i�j��k��s���%�f���S.�qg�hj�O	�)8�l��;��I��.��l��w�G
���i'�@��R����
��%�`4�[`���� ��D�Bb������@�L��x&x'H����@�� @�0�d@��@��Unknown������������	G��*�Ax�	�Times New Roman5��Symbol3.��*�Cx�	�Arial_��TimesNewRomanPSMTMS Mincho7���@�Cambria7.���@�CalibriY�	CG TimesTimes New Roman5.��.�[`�)�TahomaA���$B�Cambria Math"q���h�*g8�%�F4�k�zs�\Is�\I!������20/�/�3�q���HP	�$P����������������������L12!xx����
May 5th, 2013MarinaWFUHS����Oh��+'��0���������	
8DP
\hpx��May 5th, 2013MarinaNormalWFUHS363Microsoft Office Word@\�-@l����@�k�a�@P}(|�s�����՜.��+,��D��՜.��+,��<�hp��������
���ToshibaI\/�May 5th, 2013Title�i 8@_PID_HLINKS�ATi�#4e,http://www.ncbi.nlm.nih.gov/pubmed/23673137(Db_http://www.ncbi.nlm.nih.gov/pubmed?term=Lai%20CL%5BAuthor%5D&cauthor=true&cauthor_uid=20683932#@__http://www.ncbi.nlm.nih.gov/pubmed?term=Han%20KH%5BAuthor%5D&cauthor=true&cauthor_uid=20683932g\ahttp://www.ncbi.nlm.nih.gov/pubmed?term=Schiff%20E%5BAuthor%5D&cauthor=true&cauthor_uid=20683932XeYmhttp://www.ncbi.nlm.nih.gov/pubmed?term=Vafiadis-Zoumbouli%20I%5BAuthor%5D&cauthor=true&cauthor_uid=21270118w]Vkhttp://www.ncbi.nlm.nih.gov/pubmed?term=Raptopoulou-Gigi%20M%5BAuthor%5D&cauthor=true&cauthor_uid=21270118qSahttp://www.ncbi.nlm.nih.gov/pubmed?term=Vourli%20G%5BAuthor%5D&cauthor=true&cauthor_uid=212701187P`http://www.ncbi.nlm.nih.gov/pubmed?term=Yuen%20MF%5BAuthor%5D&cauthor=true&cauthor_uid=22806323"EM_http://www.ncbi.nlm.nih.gov/pubmed?term=Lai%20CL%5BAuthor%5D&cauthor=true&cauthor_uid=22806323+2J,http://www.ncbi.nlm.nih.gov/pubmed/16391218	
GAhttp://www.ncbi.nlm.nih.gov/pubmed/?term=merchante+n%2C+merino+e GDchttp://www.ncbi.nlm.nih.gov/pubmed?term=Galindo%20MJ%5BAuthor%5D&cauthor=true&cauthor_uid=22955438"Aqhttp://www.ncbi.nlm.nih.gov/pubmed?term=Delgado-Fern%C3%A1ndez%20M%5BAuthor%5D&cauthor=true&cauthor_uid=22955438So>`http://www.ncbi.nlm.nih.gov/pubmed?term=Jover%20F%5BAuthor%5D&cauthor=true&cauthor_uid=22955438n;nhttp://www.ncbi.nlm.nih.gov/pubmed?term=L%C3%B3pez-Aldeguer%20J%5BAuthor%5D&cauthor=true&cauthor_uid=22955438`8ahttp://www.ncbi.nlm.nih.gov/pubmed?term=Merino%20E%5BAuthor%5D&cauthor=true&cauthor_uid=22955438Iv5dhttp://www.ncbi.nlm.nih.gov/pubmed?term=Merchante%20N%5BAuthor%5D&cauthor=true&cauthor_uid=22955438Q2bhttp://www.ncbi.nlm.nih.gov/pubmed?term=Taylor%20LE%5BAuthor%5D&cauthor=true&cauthor_uid=17692986Sr/`http://www.ncbi.nlm.nih.gov/pubmed?term=Naqvi%20Z%5BAuthor%5D&cauthor=true&cauthor_uid=17692986Xo,`http://www.ncbi.nlm.nih.gov/pubmed?term=Marks%20K%5BAuthor%5D&cauthor=true&cauthor_uid=17692986y)_http://www.ncbi.nlm.nih.gov/pubmed?term=Xiao%20P%5BAuthor%5D&cauthor=true&cauthor_uid=17692986+O&_http://www.ncbi.nlm.nih.gov/pubmed?term=Fox%20RK%5BAuthor%5D&cauthor=true&cauthor_uid=17692986Qe#dhttp://www.ncbi.nlm.nih.gov/pubmed?term=Br%C3%A4u%20N%5BAuthor%5D&cauthor=true&cauthor_uid=17692986 Bhttp://www.ncbi.nlm.nih.gov/pubmed/?term=macdonald+dc%2C+nelson+mgahttp://www.ncbi.nlm.nih.gov/pubmed?term=Powles%20T%5BAuthor%5D&cauthor=true&cauthor_uid=18350596Zi`http://www.ncbi.nlm.nih.gov/pubmed?term=Bower%20M%5BAuthor%5D&cauthor=true&cauthor_uid=18350596vahttp://www.ncbi.nlm.nih.gov/pubmed?term=Nelson%20M%5BAuthor%5D&cauthor=true&cauthor_uid=18350596A ehttp://www.ncbi.nlm.nih.gov/pubmed?term=MacDonald%20DC%5BAuthor%5D&cauthor=true&cauthor_uid=18350596)3,http://www.ncbi.nlm.nih.gov/pubmed/19202627Bhttp://www.ncbi.nlm.nih.gov/pubmed/?term=matthews+gv%2C+manzini+pzchttp://www.ncbi.nlm.nih.gov/pubmed?term=Matchaba%20G%5BAuthor%5D&cauthor=true&cauthor_uid=21716078n_http://www.ncbi.nlm.nih.gov/pubmed?term=Maja%20P%5BAuthor%5D&cauthor=true&cauthor_uid=21716078Mf`http://www.ncbi.nlm.nih.gov/pubmed?term=Khabo%20P%5BAuthor%5D&cauthor=true&cauthor_uid=21716078j]http://www.ncbi.nlm.nih.gov/pubmed?term=Hu%20Z%5BAuthor%5D&cauthor=true&cauthor_uid=21716078+�bhttp://www.ncbi.nlm.nih.gov/pubmed?term=Manzini%20P%5BAuthor%5D&cauthor=true&cauthor_uid=21716078/�dhttp://www.ncbi.nlm.nih.gov/pubmed?term=Matthews%20GV%5BAuthor%5D&cauthor=true&cauthor_uid=21716078`�chttp://www.ncbi.nlm.nih.gov/pubmed?term=Antinori%20A%5BAuthor%5D&cauthor=true&cauthor_uid=123745213�bhttp://www.ncbi.nlm.nih.gov/pubmed?term=Girardi%20E%5BAuthor%5D&cauthor=true&cauthor_uid=12374521Cm�`http://www.ncbi.nlm.nih.gov/pubmed?term=Puoti%20M%5BAuthor%5D&cauthor=true&cauthor_uid=12374521(3�,http://www.ncbi.nlm.nih.gov/pubmed/19435436(=�,http://www.ncbi.nlm.nih.gov/pubmed/19550291_d�`http://www.ncbi.nlm.nih.gov/pubmed?term=Phair%20J%5BAuthor%5D&cauthor=true&cauthor_uid=19550291dL�chttp://www.ncbi.nlm.nih.gov/pubmed?term=D'Acunto%20K%5BAuthor%5D&cauthor=true&cauthor_uid=195502912�`http://www.ncbi.nlm.nih.gov/pubmed?term=Witt%20MD%5BAuthor%5D&cauthor=true&cauthor_uid=19550291Nd�`http://www.ncbi.nlm.nih.gov/pubmed?term=Young%20S%5BAuthor%5D&cauthor=true&cauthor_uid=195502912S�chttp://www.ncbi.nlm.nih.gov/pubmed?term=Seaberg%20EC%5BAuthor%5D&cauthor=true&cauthor_uid=19550291'�dhttp://www.ncbi.nlm.nih.gov/pubmed?term=Hoffmann%20CJ%5BAuthor%5D&cauthor=true&cauthor_uid=19550291*<�,http://www.ncbi.nlm.nih.gov/pubmed/15802978yN�chttp://www.ncbi.nlm.nih.gov/pubmed?term=de%20Wit%20S%5BAuthor%5D&cauthor=true&cauthor_uid=15802978 �bhttp://www.ncbi.nlm.nih.gov/pubmed?term=Mocroft%20A%5BAuthor%5D&cauthor=true&cauthor_uid=15802978i�ehttp://www.ncbi.nlm.nih.gov/pubmed?term=Konopnicki%20D%5BAuthor%5D&cauthor=true&cauthor_uid=15802978"3�,http://www.ncbi.nlm.nih.gov/pubmed/21076274 O�nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Gonz%C3%A1lez-Lahoz%20J%5BAuthor%5D&cauthor=true&cauthor_uid=21076274Sr�`http://www.ncbi.nlm.nih.gov/pubmed?term=Vispo%20E%5BAuthor%5D&cauthor=true&cauthor_uid=21076274V}�`http://www.ncbi.nlm.nih.gov/pubmed?term=Plaza%20Z%5BAuthor%5D&cauthor=true&cauthor_uid=21076274"?�,http://www.ncbi.nlm.nih.gov/pubmed/19897410z�ehttp://www.ncbi.nlm.nih.gov/pubmed?term=Parrinello%20M%5BAuthor%5D&cauthor=true&cauthor_uid=19897410s�chttp://www.ncbi.nlm.nih.gov/pubmed?term=Simoneau%20G%5BAuthor%5D&cauthor=true&cauthor_uid=19897410#F�chttp://www.ncbi.nlm.nih.gov/pubmed?term=Mazeron%20MC%5BAuthor%5D&cauthor=true&cauthor_uid=19897410!6�,http://www.ncbi.nlm.nih.gov/pubmed/23234725}�_http://www.ncbi.nlm.nih.gov/pubmed?term=Buti%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23234725b�_http://www.ncbi.nlm.nih.gov/pubmed?term=Gane%20E%5BAuthor%5D&cauthor=true&cauthor_uid=23234725Wi�dhttp://www.ncbi.nlm.nih.gov/pubmed?term=Marcellin%20P%5BAuthor%5D&cauthor=true&cauthor_uid=23234725uc�@http://www.ncbi.nlm.nih.gov/pubmed/?term=gordon+sc%2C+krastev+zg�_http://www.ncbi.nlm.nih.gov/pubmed?term=Dinh%20P%5BAuthor%5D&cauthor=true&cauthor_uid=23364953Dj�`http://www.ncbi.nlm.nih.gov/pubmed?term=Sperl%20J%5BAuthor%5D&cauthor=true&cauthor_uid=23364953~�chttp://www.ncbi.nlm.nih.gov/pubmed?term=Petersen%20J%5BAuthor%5D&cauthor=true&cauthor_uid=23364953`�ahttp://www.ncbi.nlm.nih.gov/pubmed?term=Horban%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23364953&�bhttp://www.ncbi.nlm.nih.gov/pubmed?term=Krastev%20Z%5BAuthor%5D&cauthor=true&cauthor_uid=23364953jY�bhttp://www.ncbi.nlm.nih.gov/pubmed?term=Gordon%20SC%5BAuthor%5D&cauthor=true&cauthor_uid=23364953$>�,http://www.ncbi.nlm.nih.gov/pubmed/20955704(�bhttp://www.ncbi.nlm.nih.gov/pubmed?term=Krastev%20Z%5BAuthor%5D&cauthor=true&cauthor_uid=20955704g�dhttp://www.ncbi.nlm.nih.gov/pubmed?term=De%20Man%20RA%5BAuthor%5D&cauthor=true&cauthor_uid=20955704j
�_http://www.ncbi.nlm.nih.gov/pubmed?term=Gane%20E%5BAuthor%5D&cauthor=true&cauthor_uid=20955704 :�,http://www.ncbi.nlm.nih.gov/pubmed/23465393(:�,http://www.ncbi.nlm.nih.gov/pubmed/19210695Y�Ahttp://www.ncbi.nlm.nih.gov/pubmed/?term=arendt+e%2C+jaroszewiczLa~dhttp://www.ncbi.nlm.nih.gov/pubmed?term=Mederacke%20I%5BAuthor%5D&cauthor=true&cauthor_uid=23131018iU{bhttp://www.ncbi.nlm.nih.gov/pubmed?term=Zacher%20BJ%5BAuthor%5D&cauthor=true&cauthor_uid=23131018(Exfhttp://www.ncbi.nlm.nih.gov/pubmed?term=Meyer-Olson%20D%5BAuthor%5D&cauthor=true&cauthor_uid=23131018Jtudhttp://www.ncbi.nlm.nih.gov/pubmed?term=Rockstroh%20J%5BAuthor%5D&cauthor=true&cauthor_uid=23131018/rfhttp://www.ncbi.nlm.nih.gov/pubmed?term=Jaroszewicz%20J%5BAuthor%5D&cauthor=true&cauthor_uid=23131018hoahttp://www.ncbi.nlm.nih.gov/pubmed?term=Arendt%20E%5BAuthor%5D&cauthor=true&cauthor_uid=23131018'5l,http://www.ncbi.nlm.nih.gov/pubmed/23315316I3iahttp://www.ncbi.nlm.nih.gov/pubmed?term=Lewin%20SR%5BAuthor%5D&cauthor=true&cauthor_uid=23315316'f`http://www.ncbi.nlm.nih.gov/pubmed?term=Dore%20GJ%5BAuthor%5D&cauthor=true&cauthor_uid=23315316|cahttp://www.ncbi.nlm.nih.gov/pubmed?term=Bowden%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23315316%3`,http://www.ncbi.nlm.nih.gov/pubmed/23435302+]bhttp://www.ncbi.nlm.nih.gov/pubmed?term=Agarwal%20K%5BAuthor%5D&cauthor=true&cauthor_uid=23435302ZoZ`http://www.ncbi.nlm.nih.gov/pubmed?term=Carey%20I%5BAuthor%5D&cauthor=true&cauthor_uid=23435302DzW`http://www.ncbi.nlm.nih.gov/pubmed?term=Bruce%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23435302%6T,http://www.ncbi.nlm.nih.gov/pubmed/23196935
hQehttp://www.ncbi.nlm.nih.gov/pubmed?term=Chalamilla%20G%5BAuthor%5D&cauthor=true&cauthor_uid=23196935cN_http://www.ncbi.nlm.nih.gov/pubmed?term=Aris%20E%5BAuthor%5D&cauthor=true&cauthor_uid=23196935bK_http://www.ncbi.nlm.nih.gov/pubmed?term=Nagu%20T%5BAuthor%5D&cauthor=true&cauthor_uid=23196935 :H,http://www.ncbi.nlm.nih.gov/pubmed/21933423'9E,http://www.ncbi.nlm.nih.gov/pubmed/20801123/8B,http://www.ncbi.nlm.nih.gov/pubmed/20800920%0?,http://www.ncbi.nlm.nih.gov/pubmed/19632954 0<,http://www.ncbi.nlm.nih.gov/pubmed/19584701I39ahttp://www.ncbi.nlm.nih.gov/pubmed?term=Lewin%20SR%5BAuthor%5D&cauthor=true&cauthor_uid=23315316'6`http://www.ncbi.nlm.nih.gov/pubmed?term=Dore%20GJ%5BAuthor%5D&cauthor=true&cauthor_uid=23315316|3ahttp://www.ncbi.nlm.nih.gov/pubmed?term=Bowden%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23315316 80,http://www.ncbi.nlm.nih.gov/pubmed/17918088 <-,http://www.ncbi.nlm.nih.gov/pubmed/17682999.1*,http://www.ncbi.nlm.nih.gov/pubmed/16989608k'chttp://www.ncbi.nlm.nih.gov/pubmed?term=Barreiro%20P%5BAuthor%5D&cauthor=true&cauthor_uid=16989608Nl$phttp://www.ncbi.nlm.nih.gov/pubmed?term=Mart%C3%ADn-Carbonero%20L%5BAuthor%5D&cauthor=true&cauthor_uid=16989608d!ahttp://www.ncbi.nlm.nih.gov/pubmed?term=Camino%20N%5BAuthor%5D&cauthor=true&cauthor_uid=16989608(5,http://www.ncbi.nlm.nih.gov/pubmed/12441815/bhttp://www.ncbi.nlm.nih.gov/pubmed?term=Soriano%20V%5BAuthor%5D&cauthor=true&cauthor_uid=12441815*Inhttp://www.ncbi.nlm.nih.gov/pubmed?term=Gonz%C3%A1lez-Lahoz%20J%5BAuthor%5D&cauthor=true&cauthor_uid=12441815udhttp://www.ncbi.nlm.nih.gov/pubmed?term=R%C3%ADos%20P%5BAuthor%5D&cauthor=true&cauthor_uid=12441815{dhttp://www.ncbi.nlm.nih.gov/pubmed?term=D%C3%ADaz%20B%5BAuthor%5D&cauthor=true&cauthor_uid=12441815tlhttp://www.ncbi.nlm.nih.gov/pubmed?term=P%C3%A9rez-Olmeda%20M%5BAuthor%5D&cauthor=true&cauthor_uid=12441815jhttp://www.ncbi.nlm.nih.gov/pubmed?term=N%C3%BA%C3%B1ez%20M%5BAuthor%5D&cauthor=true&cauthor_uid=12441815.>	,http://www.ncbi.nlm.nih.gov/pubmed/16964824uehttp://www.ncbi.nlm.nih.gov/pubmed?term=Mu%C3%B1oz%20A%5BAuthor%5D&cauthor=true&cauthor_uid=12493258mchttp://www.ncbi.nlm.nih.gov/pubmed?term=Visscher%20B%5BAuthor%5D&cauthor=true&cauthor_uid=12493258Xj`http://www.ncbi.nlm.nih.gov/pubmed?term=Phair%20J%5BAuthor%5D&cauthor=true&cauthor_uid=12493258	

 !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~�����������������������������������������������������������������������������������������������������������������������������������	

�������� !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRS����������������X����������������������������������������������������������������������������������������������������������������������������������������������������������������Root Entry��������	�F���)(|�Z�1Table����������]WordDocument��������.�SummaryInformation(����DocumentSummaryInformation8�������������jCompObj������������r������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������
����	�F Microsoft Word 97-2003 Document
MSWordDocWord.Document.8�9�q

Youez - 2016 - github.com/yon3zu
LinuXploit